
Yoshiya Tanaka

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2781484/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Abatacept ameliorates both glandular and extraglandular involvements in patients with Sj¶gren's syndrome associated with rheumatoid arthritis: Findings from an open-label, multicentre, 1-year, prospective study: The ROSE (Rheumatoid Arthritis with Orencia Trial Toward Sj¶gren's Syndrome) Tj ETQq1	1 ¹ 0.78431	l ⁴ rgBT /O∨
2	Rituximab in the real-world treatment of lupus nephritis: A retrospective cohort study in Japan. Modern Rheumatology, 2023, 33, 145-153.	1.8	6
3	Usefulness of ultrasound as a predictor of elderly-onset rheumatoid arthritis with polymyalgia rheumatica-like onset. Modern Rheumatology, 2023, 33, 318-322.	1.8	5
4	Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years. Modern Rheumatology, 2023, 33, 64-72.	1.8	2
5	Long-term safety and efficacy of belimumab in Japanese patients with SLE: A 7-year open-label continuation study. Modern Rheumatology, 2023, 33, 122-133.	1.8	2
6	Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE. Rheumatology, 2023, 62, 617-628.	1.9	9
7	Systemic Lupus Erythematosus: Targeted Literature Review of the Epidemiology, Current Treatment, and Disease Burden in the Asia Pacific Region. Arthritis Care and Research, 2022, 74, 187-198.	3.4	25
8	Treatment of rheumatoid arthritis after regression of lymphoproliferative disorders in patients treated with methotrexate: a retrospective, multi-center descriptive study. Modern Rheumatology, 2022, 32, 41-49.	1.8	7
9	Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2). Modern Rheumatology, 2022, 32, 59-67.	1.8	6
10	Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials. Modern Rheumatology, 2022, 32, 1-11.	1.8	21
11	Digital pitting scars are associated with a severe disease course and death in systemic sclerosis: a study from the EUSTAR cohort. Rheumatology, 2022, 61, 1141-1147.	1.9	8
12	Blood glucose dynamics during sleep in patients with obstructive sleep apnea and normal glucose tolerance: effects of CPAP therapy. Sleep and Breathing, 2022, 26, 771-781.	1.7	4
13	Prophylaxis against pneumocystis pneumonia in rheumatoid arthritis patients treated with b/tsDMARDs: insights from 3787 cases in the FIRST registry. Rheumatology, 2022, 61, 1831-1840.	1.9	14
14	Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND. Journal of Rheumatology, 2022, 49, 133-141.	2.0	5
15	Sarilumab monotherapy <i>vs</i> sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis. Rheumatology, 2022, 61, 2596-2602.	1.9	4
16	Relationship between blood glucose variability in ambulatory glucose profile and standardized continuous glucose monitoring metrics: Subanalysis of a prospective cohort study. Diabetes, Obesity and Metabolism, 2022, 24, 82-93.	4.4	3
17	Low Vitamin D Levels are Associated with Vascular Endothelial Dysfunction in Patients with Poorly Controlled Type 2 Diabetes: A Retrospective Study. Journal of Atherosclerosis and Thrombosis, 2022, 29, 242-251.	2.0	6
18	Impact of age on the efficacy and safety of peficitinib (ASP015K) for the treatment of rheumatoid arthritis. Modern Rheumatology, 2022, 32, 696-707.	1.8	1

#	Article	IF	CITATIONS
19	A pooled analysis of serious infections and herpes zoster-related disease in Asian patients with rheumatoid arthritis treated with peficitinib (ASP015K) over a median of 3 years. Modern Rheumatology, 2022, 32, 708-717.	1.8	2
20	Immunogenicity of sarilumab and impact on safety and efficacy in Japanese patients with rheumatoid arthritis: analysis of two Phase 3 randomised clinical trials. Modern Rheumatology, 2022, 32, 686-695.	1.8	2
21	Neuropsychiatric systemic lupus erythematosus detected using extravascular spillage signal on dynamic magnetic resonance imaging (Ktrans). Rheumatology, 2022, 61, SI102-SI104.	1.9	1
22	Novel susceptibility loci for steroid-associated osteonecrosis of the femoral head in systemic lupus erythematosus. Human Molecular Genetics, 2022, 31, 1082-1095.	2.9	1
23	Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. Annals of the Rheumatic Diseases, 2022, 81, 184-192.	0.9	40
24	An enhanced mitochondrial function through glutamine metabolism in plasmablast differentiation in systemic lupus erythematosus. Rheumatology, 2022, 61, 3049-3059.	1.9	19
25	Clinical features of Behçet's disease patients with joint symptoms in Japan: A national multicenter study. Modern Rheumatology, 2022, 32, 1146-1152.	1.8	1
26	Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis. Rheumatology and Therapy, 2022, 9, 191-206.	2.3	4
27	Efficacy and safety of abatacept in biologic-naÃ ⁻ ve patients with active rheumatoid arthritis by background methotrexate dose: <i>post hoc</i> analysis of a randomized, placebo-controlled, phase 4 study. Modern Rheumatology, 2022, 32, 500-507.	1.8	2
28	Apremilast in a Japanese subgroup with Behçet's syndrome: Results from a Phase 3, randomised, double-blind, placebo-controlled study. Modern Rheumatology, 2022, 32, 413-421.	1.8	5
29	Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1). Modern Rheumatology, 2022, 32, 263-272.	1.8	10
30	Long-term safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis: 3-year follow-up of a postmarketing surveillance. Modern Rheumatology, 2022, 32, 508-516.	1.8	2
31	Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3). Modern Rheumatology, 2022, 32, 273-283.	1.8	3
32	Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study. Scientific Reports, 2022, 12, 154.	3.3	3
33	Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nature Reviews Rheumatology, 2022, 18, 133-145.	8.0	193
34	Risk Factor Analysis for Type 2 Diabetes Patients About Hypoglycemia Using Continuous Glucose Monitoring: Results from a Prospective Observational Study. Diabetes Technology and Therapeutics, 2022, 24, 435-445.	4.4	5
35	A case of simultaneous onset of highly active systemic lupus erythematosus and IgG4-related renal disease. Modern Rheumatology Case Reports, 2022, 6, 178-182.	0.7	1
36	Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study. Rheumatology, 2022, 61, 4273-4285.	1.9	3

#	Article	IF	CITATIONS
37	Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study. RMD Open, 2022, 8, e002012.	3.8	50
38	The Efficacy and Safety of Anifrolumab in Japanese Patients With Systemic Lupus Erythematosus: TULIP-2 Subanalysis. Modern Rheumatology, 2022, , .	1.8	3
39	Pathological relevance and treatment perspective of JAK targeting in systemic lupus erythematosus. Expert Review of Clinical Immunology, 2022, , .	3.0	5
40	Difficult-to-treat rheumatoid arthritis with respect to responsiveness to biologic/targeted synthetic DMARDs: a retrospective cohort study from the FIRST registry. Clinical and Experimental Rheumatology, 2022, 40, 86-96.	0.8	5
41	Branched chain amino acids in the treatment of polymyositis and dermatomyositis: a phase II/III, multi-centre, randomized controlled trial. Rheumatology, 2022, , .	1.9	0
42	Association of Viral Infection With the Development and Pathogenesis of Systemic Lupus Erythematosus. Frontiers in Medicine, 2022, 9, 849120.	2.6	14
43	Hypoglycemia induces vascular endothelial dysfunction in subjects with normal glucose tolerance. Scientific Reports, 2022, 12, 2598.	3.3	7
44	Eosinophilic granulomatosis with polyangiitis exhibits T cell activation and IgG4 immune response in the tissue; comparison with IgG4-related disease. RMD Open, 2022, 8, e002086.	3.8	5
45	A case of mixed connective tissue disease complicated by pulmonary hypertension and ascites after addition of pulmonary vasodilators. Modern Rheumatology Case Reports, 2022, , .	0.7	1
46	Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry. Arthritis Research and Therapy, 2022, 24, 61.	3.5	30
47	Dawn of Precision Medicine in Psoriatic Arthritis. Frontiers in Medicine, 2022, 9, 851892.	2.6	3
48	â€~Not at target': prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study. Arthritis Research and Therapy, 2022, 24, 70.	3.5	17
49	Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Annals of the Rheumatic Diseases, 2022, 81, 951-961.	0.9	38
50	<i>Post hoc</i> analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4). Modern Rheumatology, 2022, , .	1.8	3
51	Nailfold microvascular abnormalities are associated with a higher prevalence of pulmonary arterial hypertension in patients with MCTD. Rheumatology, 2022, 61, 4875-4884.	1.9	5
52	Short-Term Prognostic Factors in Hospitalized Herpes Zoster Patients and Its Associated Cerebro-Cardiovascular Events: A Nationwide Retrospective Cohort in Japan. Frontiers in Medicine, 2022, 9, 843809.	2.6	3
53	Allogeneic Stem Cell Transplantation for Trisomy 8-Positive Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Disease with Refractory Beh§et's Disease, Case Report and the Review of Literature. Modern Rheumatology Case Reports, 2022, , .	0.7	1
54	Associations between continuous glucose monitoring-derived metrics and HbA1c in patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2022, 186, 109836.	2.8	5

#	Article	IF	CITATIONS
55	A patient with eosinophilic granulomatosis with polyangiitis successfully weaned from corticosteroids through remission induction therapy with mepolizumab. Modern Rheumatology Case Reports, 2022, 6, 243-247.	0.7	7
56	Efficacy and safety of belimumab during maintenance therapy in patients with systemic lupus erythematosus. Rheumatology, 2022, 61, 3614-3626.	1.9	10
57	Efficacy and safety of high-dose of mycophenolate mofetil compared with cyclophosphamide pulse therapy as induction therapy in Japanese patients with proliferative lupus nephritis. Modern Rheumatology, 2022, 32, 1077-1085.	1.8	1
58	Impact of serum interleukin-22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: a retrospective study. Arthritis Research and Therapy, 2022, 24, 86.	3.5	5
59	Down-regulated Th17 cells in a patient with familial Mediterranean fever associated with amyloid A amyloidosis in the treatment of canakinumab. Modern Rheumatology Case Reports, 2022, , .	0.7	2
60	P192 Efficacy of filgotinib in rheumatoid arthritis by age, body weight, body mass index: post hoc subgroup analysis of two phase 3 trials. Rheumatology, 2022, 61, .	1.9	0
61	OA29â€∫Clinical outcomes up to week 48 of filgotinib treatment in an ongoing long-term extension trial of RA patients with inadequate response to methotrexate initially treated with filgotinib or adalimumab during the Phase 3 Parent Trial. Rheumatology, 2022, 61, .	1.9	1
62	P220 Long-term safety profile of upadacitinib in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Rheumatology, 2022, 61, .	1.9	1
63	Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials. Annals of the Rheumatic Diseases, 2022, 81, 962-969.	0.9	15
64	Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2022, 81, 1267-1272.	0.9	18
65	Phase II/III Results of a Trial of Anti–Tumor Necrosis Factor Multivalent NANOBODY Compound Ozoralizumab in Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2022, 74, 1776-1785.	5.6	25
66	Belimumab: A BAFF-specific Inhibitor for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis. , 2022, 1, 32.		0
67	Multi-trait and cross-population genome-wide association studies across autoimmune and allergic diseases identify shared and distinct genetic component. Annals of the Rheumatic Diseases, 2022, 81, 1301-1312.	0.9	21
68	Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study. Arthritis Research and Therapy, 2022, 24, .	3.5	10
69	Association Between Time in Range and Postprandial Glucose Contribution Rate in Non-Insulin-Treated Type 2 Diabetes Patients: Inverse Correlation of Time in Range with Postprandial Glucose Contribution Rate. Diabetes Technology and Therapeutics, 2022, 24, 805-813.	4.4	2
70	Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2022, 81, 1556-1563.	0.9	24
71	Response to: â€~Comment on â€~Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka <i>et al</i> ' by Berkhout <i>et al</i> . Annals of the Rheumatic Diseases, 2021, 80, e173-e173.	0.9	0
72	Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study. Rheumatology, 2021, 60, 2884-2895.	1.9	14

#	Article	IF	CITATIONS
73	Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders. Modern Rheumatology, 2021, 31, 94-100.	1.8	8
74	Case of autoimmune polyendocrine syndrome typeÂ3 complicated with antiâ€Nâ€methylâ€Dâ€aspartic acidâ€receptor encephalitis. Journal of Diabetes Investigation, 2021, 12, 290-292.	2.4	0
75	A phase 2a, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral gonadotropin-releasing hormone antagonist, ASP1707, in postmenopausal female patients with rheumatoid arthritis taking methotrexate. Modern Rheumatology, 2021, 31, 53-60.	1.8	2
76	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Annals of the Rheumatic Diseases, 2021, 80, 71-87.	0.9	158
77	Conversion of T Follicular Helper Cells to T Follicular Regulatory Cells by Interleukinâ€2 Through Transcriptional Regulation in Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2021, 73, 132-142.	5.6	48
78	Rapidly progressive glomerulonephritis after introduction of certolizumab pegol: a case report. Modern Rheumatology Case Reports, 2021, 5, 11-15.	0.7	4
79	Efficacy and Safety of E6011, an Antiâ€Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Doubleâ€Blind, Placeboâ€Controlled Phase II Study. Arthritis and Rheumatology, 2021, 73, 587-595.	5.6	17
80	RANKL as a therapeutic target of rheumatoid arthritis. Journal of Bone and Mineral Metabolism, 2021, 39, 106-112.	2.7	30
81	Human dendritic cell-derived osteoclasts with high bone resorption capacity and T cell stimulation ability. Bone, 2021, 142, 115616.	2.9	19
82	A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years. Modern Rheumatology, 2021, 31, 543-555.	1.8	6
83	Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis: the TOWER-GO study. Journal of Bone and Mineral Metabolism, 2021, 39, 446-455.	2.7	9
84	Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term studyÂ. Rheumatology, 2021, 60, 2256-2266.	1.9	12
85	Lung transplantation resulted in marked improvement of autoimmunity and scleroderma in diffuse cutaneous systemic sclerosis: a case report. Rheumatology, 2021, 60, e129-e131.	1.9	Ο
86	Osteoporosis case ascertainment strategies in European and Asian countries: a comparative review. Osteoporosis International, 2021, 32, 817-829.	3.1	21
87	Why remission is not enough: underlying disease mechanisms in RA that prevent cure. Nature Reviews Rheumatology, 2021, 17, 135-144.	8.0	49
88	Associations between urinary 6â€sulfatoxymelatonin excretion and diabetic vascular complications or arteriosclerosis in patients with typeÂ2 diabetes. Journal of Diabetes Investigation, 2021, 12, 601-609.	2.4	7
89	Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Annals of the Rheumatic Diseases, 2021, 80, 304-311.	0.9	129
90	The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries. Rheumatology, 2021, 60, 820-828.	1.9	41

#	Article	IF	CITATIONS
91	Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials. Modern Rheumatology, 2021, 31, 1-12.	1.8	52
92	Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE studies. Modern Rheumatology, 2021, 31, 34-41.	1.8	14
93	Response to tocilizumab and work productivity in patients with rheumatoid arthritis: 2-year follow-up of FIRST ACT-SC study. Modern Rheumatology, 2021, 31, 42-52.	1.8	6
94	2019 Diagnostic criteria for mixed connective tissue disease (MCTD): From the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases. Modern Rheumatology, 2021, 31, 29-33.	1.8	49
95	Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs. Rheumatology, 2021, 60, vi12-vi20.	1.9	26
96	<i>SOD2</i> mRNA as a potential biomarker for exercise: interventional and cross-sectional research in healthy subjects. Journal of Clinical Biochemistry and Nutrition, 2021, 69, 137-144.	1.4	2
97	Glucose-lowering effects of 7-day treatment with SGLT2 inhibitor confirmed by intermittently scanned continuous glucose monitoring in outpatients with type 1 diabetes. A pilot study. Endocrine Journal, 2021, 68, 361-369.	1.6	2
98	Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE). RMD Open, 2021, 7, e001465.	3.8	9
99	Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE). Arthritis Research and Therapy, 2021, 23, 9.	3.5	17
100	A phase 2 study of E6011, an anti-Fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs. Modern Rheumatology, 2021, 31, 783-789.	1.8	11
101	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. Annals of the Rheumatic Diseases, 2021, 80, 775-781.	0.9	37
102	Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program. Drug Safety, 2021, 44, 515-530.	3.2	28
103	Similarity of Response to Biologics Between Elderly-onset Rheumatoid Arthritis (EORA) and Non-EORA Elderly Patients: From the FIRST Registry. Journal of Rheumatology, 2021, 48, 1655-1662.	2.0	10
104	Enlarged glycemic variability in sulfonylurea-treated well-controlled type 2 diabetics identified using continuous glucose monitoring. Scientific Reports, 2021, 11, 4875.	3.3	5
105	The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus. Lancet Rheumatology, The, 2021, 3, e517-e531.	3.9	26
106	Estimation of treatment and prognostic factors of pneumocystis pneumonia in patients with connective tissue diseases. RMD Open, 2021, 7, e001508.	3.8	17
107	Comparative Efficacy and Safety of Peficitinib Versus Tofacitinib and Baricitinib for Treatment of Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis. Rheumatology and Therapy, 2021, 8, 729-750.	2.3	6
108	Pathological role of activated mTOR in CXCR3+ memory B cells of rheumatoid arthritis. Rheumatology, 2021, 60, 5452-5462.	1.9	7

#	Article	IF	CITATIONS
109	Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: An Overview. Journal of Clinical Medicine, 2021, 10, 1241.	2.4	25
110	Safety and Effectiveness of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis: Final Results (32 Months of Mean Peficitinib Treatment) From a Long-Term, Open-Label Extension Study in Japan, Korea, and Taiwan. Rheumatology and Therapy, 2021, 8, 425-442.	2.3	16
111	Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis. Arthritis Research and Therapy, 2021, 23, 86.	3.5	22
112	A case of systemic lupus erythematosus with marked ascites due to idiopathic non-cirrhotic portal hypertension. Modern Rheumatology Case Reports, 2021, 5, 285-291.	0.7	4
113	Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting. Annals of the Rheumatic Diseases, 2021, 80, 1130-1136.	0.9	33
114	Effects of Denosumab in Japanese Patients With Rheumatoid Arthritis Treated With Conventional Antirheumatic Drugs: 36-month Extension of a Phase III Study. Journal of Rheumatology, 2021, 48, 1663-1671.	2.0	10
115	Stimulator of Interferon Genes-associated Vasculopathy with an Onset in Infancy Diagnosed after the Development of Atypical Pulmonary Lesions During Treatment as Juvenile Idiopathic Arthritis. Internal Medicine, 2021, 60, 1109-1114.	0.7	4
116	Relationship between glycemic intraday variations evaluated in continuous glucose monitoring and HbA1c variability in type 2 diabetes: pilot study. Diabetology and Metabolic Syndrome, 2021, 13, 45.	2.7	5
117	The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan. Drug Safety, 2021, 44, 711-722.	3.2	15
118	Fatal hemoperitoneum due to rupture of mesenteric artery in remission state of microscopic polyangiitis, concomitant with severe hypertension and posterior reversible encephalopathy syndrome: an autopsy case report. CEN Case Reports, 2021, 10, 549-558.	0.9	1
119	Prevention of infective complications in systemic lupus erythematosus: A systematic literature review for the APLAR consensus statements. International Journal of Rheumatic Diseases, 2021, 24, 880-895.	1.9	11
120	Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVIDâ€19 pandemic. International Journal of Rheumatic Diseases, 2021, 24, 733-745.	1.9	24
121	Differentiation, functions, and roles of T follicular regulatory cells in autoimmune diseases. Inflammation and Regeneration, 2021, 41, 14.	3.7	17
122	Work Environment-related Stress Factors are Correlated with Diabetes Development in Workers with Impaired Glucose Tolerance: A 5-year Follow-up Study Using the Brief Job Stress Questionnaire (BJSQ). Journal of UOEH, 2021, 43, 183-196.	0.6	2
123	Validity of claimsâ€based algorithms for selected cancers in Japan: Results from the VALIDATEâ€J study. Pharmacoepidemiology and Drug Safety, 2021, 30, 1153-1161.	1.9	18
124	Serum TNFα levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study. Arthritis Research and Therapy, 2021, 23, 154.	3.5	6
125	Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea. RMD Open, 2021, 7, e001629.	3.8	17
126	Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis. Arthritis Research and Therapy, 2021, 23, 221.	3.5	7

#	Article	IF	CITATIONS
127	Immune recognition of lysyl-tRNA synthetase and isoleucyl-tRNA synthetase by anti-OJ antibody-positive sera. Journal of Autoimmunity, 2021, 122, 102680.	6.5	14
128	Therapeutic perspectives on the metabolism of lymphocytes in patients with rheumatoid arthritis and systemic lupus erythematosus. Expert Review of Clinical Immunology, 2021, 17, 1121-1130.	3.0	3
129	A Japanese Patient with Anti-PM/Scl and Centromere Antibody-Positive Scleroderma-Amyopathic Dermatomyositis Overlap Syndrome Who Developed Renal Crisis. Modern Rheumatology Case Reports, 2021, , .	0.7	1
130	Genome-oriented treatment strategies for autoimmune diseases. Inflammation and Regeneration, 2021, 41, 30.	3.7	0
131	Clinical relevance of T follicular helper cells in systemic lupus erythematosus. Expert Review of Clinical Immunology, 2021, 17, 1143-1150.	3.0	9
132	Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis—a comprehensive review. Arthritis Research and Therapy, 2021, 23, 3.	3.5	18
133	Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Annals of the Rheumatic Diseases, 2021, 80, 848-858.	0.9	123
134	Subclinical synovitis detected by magnetic resonance imaging and ultrasonography following clinical remission in patients with rheumatoid arthritis: A retrospective study. Rheumatology & Autoimmunity, 2021, 1, 7-15.	0.8	1
135	mTOR activation in CD8+ cells contributes to disease activity of rheumatoid arthritis and increases therapeutic response to TNF inhibitors. Rheumatology, 2021, , .	1.9	4
136	Association between ultrasound images and patient-reported outcomes in the treatment of rheumatoid arthritis: a retrospective study. BMC Rheumatology, 2021, 5, 49.	1.6	0
137	Discovery of a novel Igβ and FcγRIIB cross-linking antibody, ASP2713, and its potential application in the treatment of systemic lupus erythematosus. International Immunopharmacology, 2021, 101, 108343.	3.8	0
138	Efficacy of once-weekly teriparatide for primary prevention of glucocorticoid-induced osteoporosis: A post hoc analysis of the TOWER-GO study. Modern Rheumatology, 2021, , .	1.8	0
139	Eplerenone Improves Vascular Endothelial Function in Patients with Primary Aldosteronism: A Pilot Study. Journal of UOEH, 2021, 43, 379-384.	0.6	0
140	Difficult-to-treat rheumatoid arthritis with respect to responsiveness to biologic/targeted synthetic DMARDs: a retrospective cohort study from the FIRST registry. Clinical and Experimental Rheumatology, 2021, , .	0.8	0
141	Prevention and management of herpes zoster in patients with rheumatoid arthritis and psoriatic arthritis: a clinical review. Clinical and Experimental Rheumatology, 2021, , .	0.8	1
142	T helper cells expressing fractalkine receptor and bearing T follicular helper 1-like cell functions in patients with IgG4-related disease. Rheumatology, 2021, , .	1.9	1
143	Rituximab in remission induction and maintenance therapy for microscopic polyangiitis associated with gastric cancer: A case report. Modern Rheumatology Case Reports, 2021, , .	0.7	0
144	Involvement of IncRNA IL21-AS1 in interleukin-2 and T follicular regulatory cell activation in systemic lupus erythematosus. Arthritis Research and Therapy, 2021, 23, 302.	3.5	12

#	Article	IF	CITATIONS
145	Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials. Modern Rheumatology, 2020, 30, 36-43.	1.8	44
146	Safety and tolerability of sifalimumab, an anti-interferon-α monoclonal antibody, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study. Modern Rheumatology, 2020, 30, 93-100.	1.8	23
147	Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study. Modern Rheumatology, 2020, 30, 101-108.	1.8	26
148	Skeletal unloading reduces cluster of differentiation (CD) 38 expression in the bone marrow and osteoblasts of mice. Journal of Orthopaedic Science, 2020, 25, 331-337.	1.1	5
149	Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial. Modern Rheumatology, 2020, 30, 313-320.	1.8	11
150	Impaired expression of innate immunity-related genes in IgG4-related disease: A possible mechanism in the pathogenesis of IgG4-RD. Modern Rheumatology, 2020, 30, 551-557.	1.8	5
151	The development of quality indicators for systemic lupus erythematosus using electronic health data: A modified RAND appropriateness method. Modern Rheumatology, 2020, 30, 525-531.	1.8	6
152	Predictive value of serum amyloid a levels for requirement of concomitant methotrexate in tocilizumab initiation: A <i>post hoc</i> analysis of the SURPRISE study. Modern Rheumatology, 2020, 30, 442-449.	1.8	2
153	Focal Eosinophilic Myositis. Internal Medicine, 2020, 59, 141-141.	0.7	1
154	Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA). Modern Rheumatology, 2020, 30, 239-248.	1.8	17
155	Effectiveness, safety, and methotrexate dose-tapering pattern over two years of treatment with adalimumab and ≥12 mg/week methotrexate for early rheumatoid arthritis: Results of the HAWK postmarketing surveillance study in Japan. Modern Rheumatology, 2020, 30, 424-433.	1.8	1
156	A case of systemic lupus erythematosus in which Cushing's syndrome caused by adrenal adenoma accidentally occurred during long-term maintenance therapy with corticosteroids. Modern Rheumatology Case Reports, 2020, 4, 34-38.	0.7	1
157	Validity and responsiveness of the Work Functioning Impairment Scale (WFun) in rheumatoid arthritis patients: A multicenter prospective study. Modern Rheumatology, 2020, 30, 821-827.	1.8	7
158	First external validation of sensitivity and specificity of the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for idiopathic inflammatory myopathies with a Japanese cohort. Annals of the Rheumatic Diseases, 2020, 79, 387-392.	0.9	17
159	An autopsy case of a patient with systemic sclerosis who developed marked pulmonary hypertension because of pulmonary tumor thrombotic microangiopathy caused by gastric carcinoma. Modern Rheumatology Case Reports, 2020, 4, 56-62.	0.7	1
160	Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial. Annals of the Rheumatic Diseases, 2020, 79, 94-102.	0.9	13
161	Safety of baricitinib in East Asian patients with moderateâ€ŧoâ€severe active rheumatoid arthritis: An integrated analysis from clinical trials. International Journal of Rheumatic Diseases, 2020, 23, 65-73.	1.9	12
162	Is precision medicine possible in rheumatic diseases? Lessons from selective use of targeted therapies in patients with psoriatic arthritis. Expert Review of Clinical Immunology, 2020, 16, 199-206.	3.0	7

#	Article	IF	CITATIONS
163	Trial of Anifrolumab in Active Systemic Lupus Erythematosus. New England Journal of Medicine, 2020, 382, 211-221.	27.0	725
164	5-year remission rate after the discontinuation of adalimumab in patients with rheumatoid arthritis: Long-term follow-up results of the HONOR study. Modern Rheumatology, 2020, 30, 799-806.	1.8	5
165	In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors. Rheumatology, 2020, 59, 1957-1968.	1.9	20
166	The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4â€Related Disease. Arthritis and Rheumatology, 2020, 72, 7-19.	5.6	292
167	Critical roles of super-enhancers in the pathogenesis of autoimmune diseases. Inflammation and Regeneration, 2020, 40, 16.	3.7	12
168	Potential of B-cell-targeting therapy in overcoming multidrug resistance and tissue invasiveness associated with P-glycoprotein expressing-B cell compartments. Immunological Medicine, 2020, 44, 1-10.	2.6	3
169	P210 Efficacy and safety of filgotinib for patients with RA with inadequate response to methotrexate: FINCH1 primary outcome results. Rheumatology, 2020, 59, .	1.9	1
170	Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. Lupus Science and Medicine, 2020, 7, e000424.	2.7	35
171	<p>Emerging Role of Fractalkine in the Treatment of Rheumatic Diseases</p> . ImmunoTargets and Therapy, 2020, Volume 9, 241-253.	5.8	15
172	Su1862 POOLED SAFETY ANALYSES FROM PHASE 3 STUDIES OF FILGOTINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS. Gastroenterology, 2020, 158, S-679.	1.3	0
173	O09 Pooled safety analyses from Phase 3 studies of filgotinib in patients with RA. Rheumatology, 2020, 59, .	1.9	0
174	Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction. RMD Open, 2020, 6, e001249.	3.8	8
175	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. Annals of the Rheumatic Diseases, 2020, 79, 1333-1339.	0.9	35
176	Amiselimod, a sphingosine 1-phosphate receptor-1 modulator, for systemic lupus erythematosus: A multicenter, open-label exploratory study. Lupus, 2020, 29, 1902-1913.	1.6	14
177	Changes in endothelial function during educational hospitalization and the contributor to improvement of endothelial function in type 2 diabetes mellitus. Scientific Reports, 2020, 10, 15384.	3.3	5
178	O8â€Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematosus in men, ethnicities, and early disease. , 2020, , .		0
179	Rheumatoid arthritis. Inflammation and Regeneration, 2020, 40, 20.	3.7	52
180	COVIDâ€19 infection in patients with systemic lupus erythematosus: Data from the Asia Pacific Lupus Collaboration. International Journal of Rheumatic Diseases, 2020, 23, 1255-1257.	1.9	12

#	Article	IF	CITATIONS
181	Severe pulmonary arterial hypertension and interstitial pneumonia related to systemic lupus erythematosus successfully treated with mycophenolate mofetil: A novel case report. Lupus, 2020, 29, 1955-1960.	1.6	5
182	A wide perspective of targeted therapies for precision medicine in autoimmune diseases. Expert Review of Precision Medicine and Drug Development, 2020, 5, 447-453.	0.7	3
183	Relationship between interstitial glucose variability in ambulatory glucose profile and standardized continuous glucose monitoring metrics; a pilot study. Diabetology and Metabolic Syndrome, 2020, 12, 70.	2.7	4
184	Enhanced Fatty Acid Synthesis Leads to Subset Imbalance and IFN-Î ³ Overproduction in T Helper 1 Cells. Frontiers in Immunology, 2020, 11, 593103.	4.8	12
185	Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open, 2020, 6, e001395.	3.8	100
186	ASP5094, a humanized monoclonal antibody against integrin alpha-9, did not show efficacy in patients with rheumatoid arthritis refractory to methotrexate: results from a phase 2a, randomized, double-blind, placebo-controlled trial. Arthritis Research and Therapy, 2020, 22, 252.	3.5	10
187	Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2020, 22, 115.	3.5	11
188	P209 Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the select Phase 3 clinical programme. Rheumatology, 2020, 59, .	1.9	2
189	Interleukin-23 drives expansion of Thelper 17 cells through epigenetic regulation by signal transducer and activators of transcription 3 in lupus patients. Rheumatology, 2020, 59, 3058-3069.	1.9	15
190	Fulminant Type 1 Diabetes with Diversity in Peripheral Blood Lymphocytes: A Case Report. Journal of UOEH, 2020, 42, 57-62.	0.6	0
191	Care for patients with rheumatic diseases during COVIDâ€19 pandemic: A position statement from APLAR. International Journal of Rheumatic Diseases, 2020, 23, 717-722.	1.9	21
192	A review of upadacitinib in rheumatoid arthritis. Modern Rheumatology, 2020, 30, 779-787.	1.8	35
193	Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation. Arthritis Research and Therapy, 2020, 22, 141.	3.5	10
194	Systemic lupus erythematosus with repeated protein-losing enteropathy resulting from different pathological conditions: a case report. Modern Rheumatology Case Reports, 2020, 4, 229-232.	0.7	1
195	Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry. Arthritis Research and Therapy, 2020, 22, 136.	3.5	16
196	Stateâ€ofâ€ŧheâ€art treatment of systemic lupus erythematosus. International Journal of Rheumatic Diseases, 2020, 23, 465-471.	1.9	85
197	Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA). Journal of Bone and Mineral Metabolism, 2020, 38, 522-532.	2.7	20
198	Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan. Arthritis Research and Therapy, 2020, 22, 47.	3.5	21

#	Article	IF	CITATIONS
199	Short-term effectiveness of ixekizumab to refractory psoriatic arthritis with spondyloarthritis: two case reports. Modern Rheumatology Case Reports, 2020, 4, 176-180.	0.7	1
200	Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study. Arthritis Research and Therapy, 2020, 22, 41.	3.5	10
201	A case of bone destruction caused by chronic non-bacterial osteomyelitis (CNO) successfully repaired with a tumour necrosis factor-α (TNF-α) inhibitor, adalimumab. Modern Rheumatology Case Reports, 2020, 4, 196-201.	0.7	2
202	A case of eosinophilic granulomatosis with polyangiitis as a mimicker of IgG4-related disease. Modern Rheumatology Case Reports, 2020, 4, 278-282.	0.7	2
203	Correlation between serological biomarkers of extracellular matrix turnover and lung fibrosis and pulmonary artery hypertension in patients with systemic sclerosis. International Journal of Rheumatic Diseases, 2020, 23, 532-539.	1.9	13
204	Usefulness of the index calculated as the product of levels of fasting plasma glucose and hemoglobin A1c for insulinoma screening. Endocrine Journal, 2020, 67, 509-513.	1.6	3
205	Tumour necrosis factor alpha promotes secretion of 14-3-3η by inducing necroptosis in macrophages. Arthritis Research and Therapy, 2020, 22, 24.	3.5	16
206	Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study. Rheumatology, 2020, 59, 2427-2434.	1.9	81
207	Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study. Journal of Bone and Mineral Metabolism, 2020, 38, 511-521.	2.7	3
208	Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis. International Journal of Rheumatic Diseases, 2020, 23, 316-324.	1.9	4
209	Methionine Commits Cells to Differentiate Into Plasmablasts Through Epigenetic Regulation ofBTBandCNCHomolog 2 by the MethyltransferaseEZH2. Arthritis and Rheumatology, 2020, 72, 1143-1153.	5.6	28
210	The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus. International Journal of Rheumatic Diseases, 2020, 23, 549-558.	1.9	10
211	Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials. Expert Opinion on Pharmacotherapy, 2020, 21, 1015-1025.	1.8	22
212	Five Cases of IgG4-related Disease with Nasal Mucosa and Sinus Involvement. Internal Medicine, 2020, 59, 1905-1911.	0.7	7
213	Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study. Rheumatology, 2020, 59, 3303-3313.	1.9	41
214	Response to: â€~Some concerns from Turkey' by Bilgin <i>et al</i> . Annals of the Rheumatic Diseases, 2020, 79, e16-e16.	0.9	3
215	A refractory case of a male patient with neuropsychiatric systemic lupus erythematosus with various psychiatric symptoms and MRI observations. Clinical Neuropsychopharmacology and Therapeutics, 2020, 11, 1-4.	0.3	0
216	The approach to precision medicine for the treatment of psoriatic arthritis. Immunological Medicine, 2020, 43, 98-102.	2.6	6

#	Article	IF	CITATIONS
217	Associated factors of poor treatment outcomes in patients with giant cell arteritis: clinical implication of large vessel lesions. Arthritis Research and Therapy, 2020, 22, 72.	3.5	36
218	Two patients with mixed connective tissue disease complicated by pulmonary arterial hypertension showing contrasting responses to pulmonary vasodilators. Modern Rheumatology Case Reports, 2020, 4, 253-261.	0.7	1
219	IgG4-type Multiple Myeloma with Diffuse Enlargement of the Thyroid Requiring Differentiation from IgG4-related Disease. Internal Medicine, 2020, 59, 711-714.	0.7	4
220	P-glycoprotein Expressing-B cell associated Active True Renal Lupus Vasculitis in Lupus Nephritis. , 2020, 5, .		1
221	Correlations Between Glycemic Parameters Obtained from Continuous Glucose Monitoring and Hemoglobin A1c and Glycoalbumin Levels in Type 2 Diabetes Mellitus. Journal of UOEH, 2020, 42, 299-306.	0.6	2
222	Predicting Disease Activity for Biologic Selection in Rheumatoid Arthritis. , 2020, , .		0
223	Hyperparathyroidism Which Developed after Resection of a Fibroblast Growth Factor 23-producing Tumor. Internal Medicine, 2020, 59, 2523-2527.	0.7	0
224	Mild Encephalitis/Encephalopathy with Reversible Splenial Lesions in SLE. Internal Medicine, 2020, 59, 2439-2440.	0.7	2
225	Internal Medicine, 2020, 109, 1748-1758.	0.0	Ο
226	Soluble IL-6R promotes chondrogenic differentiation of mesenchymal stem cells to enhance the repair of articular cartilage defects using a rat model for rheumatoid arthritis. Clinical and Experimental Rheumatology, 2020, 38, 670-679.	0.8	3
227	Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study. Clinical and Experimental Rheumatology, 2020, 38, 848-857.	0.8	6
228	Response of thyrotropin-secreting pituitary tumors to preoperative lanreotide therapy. Report of two cases. Neuroendocrinology Letters, 2020, 41, 10-16.	0.2	0
229	Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial. Modern Rheumatology, 2019, 29, 452-460.	1.8	13
230	<scp>l</scp> -Leucine influx through Slc7a5 regulates inflammatory responses of human B cells via mammalian target of rapamycin complex 1 signaling. Modern Rheumatology, 2019, 29, 885-891.	1.8	17
231	Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: a randomized, phase III, non-inferiority study. Rheumatology, 2019, 58, 70-79.	1.9	13
232	Effectiveness and safety of initiating adalimumab plus ≥12 mg/week methotrexate with adjustable dosing in biologic-naÃ⁻ve patients with early rheumatoid arthritis: HAWK study postmarketing surveillance in Japan. Modern Rheumatology, 2019, 29, 572-580.	1.8	7
233	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 1151-1159.	0.9	759
234	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1400-1412.	5.6	1,098

#	Article	IF	CITATIONS
235	Glycolaldehyde-modified advanced glycation end-products inhibit differentiation of human monocytes into osteoclasts via upregulation of IL-10. Bone, 2019, 128, 115034.	2.9	26
236	Efficacy and Safety of Tofogliflozin on 24-h Glucose Profile Based on Continuous Glucose Monitoring: Crossover Study of Sodium–Glucose Cotransporter 2 Inhibitor. Diabetes Technology and Therapeutics, 2019, 21, 385-392.	4.4	2
237	A Case of Marine-Lenhart Syndrome with Predominance of Plummer Disease. Journal of UOEH, 2019, 41, 165-170.	0.6	3
238	Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report. Case Reports in Rheumatology, 2019, 2019, 1-5.	0.6	8
239	The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2019, 21, 164.	3.5	24
240	Treatment with Methotrexate and Intravenous Cyclophosphamide Pulse Therapy Regulates the P-gp ⁺ CD4 ⁺ Cell-related Pathogenesis in a Representative Patient with Refractory Proliferative Lupus Nephritis. Internal Medicine, 2019, 58, 3173-3178.	0.7	1
241	Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. Annals of the Rheumatic Diseases, 2019, 78, 1305-1319.	0.9	95
242	An Autopsy Case with Cerebral Hemorrhaging due to disseminated Aspergillosis During Glucocorticoid Therapy for Overlap Syndrome of Systemic Lupus Erythematosus and Systemic Sclerosis. Internal Medicine, 2019, 58, 1023-1027.	0.7	4
243	Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twentyâ€Four–Month, Phase <scp>III</scp> Study. Arthritis and Rheumatology, 2019, 71, 878-891.	5.6	64
244	Baricitinib for systemic lupus erythematosus – Authors' reply. Lancet, The, 2019, 393, 402-403.	13.7	5
245	Real-World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients with Psoriatic Arthritis. Advances in Therapy, 2019, 36, 691-707.	2.9	11
246	Distinctive association of peripheral immune cell phenotypes with capillaroscopic microvascular patterns in systemic sclerosis. Rheumatology, 2019, 58, 2273-2283.	1.9	22
247	Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet's disease. Arthritis Research and Therapy, 2019, 21, 151.	3.5	13
248	Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis. RMD Open, 2019, 5, e000898.	3.8	14
249	Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet, The, 2019, 393, 2303-2311.	13.7	237
250	A Study of the Vascular Endothelial Function in Patients with Type 2 Diabetes Mellitus and Rheumatoid Arthritis. Internal Medicine, 2019, 58, 1383-1390.	0.7	11
251	Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2019, 78, 890-898.	0.9	22
252	Lymphocyte phenotype and its application to precision medicine in systemic autoimmune diseases✰. Seminars in Arthritis and Rheumatism, 2019, 48, 1146-1150.	3.4	18

#	Article	IF	CITATIONS
253	Addition of canagliflozin to insulin improves glycaemic control and reduces insulin dose in patients with type 2 diabetes mellitus: A randomized controlled trial. Diabetes, Obesity and Metabolism, 2019, 21, 2174-2179.	4.4	3
254	Small Molecules. , 2019, , 629-637.		0
255	Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update. Expert Review of Clinical Immunology, 2019, 15, 693-700.	3.0	31
256	Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE) Tj ETQq0 0 0 rgE	3T /Overlo 0.9	ock 10 Tf 50 6
257	2019, 78, 899-907. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan. Arthritis Research and Therapy, 2019, 21, 79.	3.5	28
258	Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asiaâ€Pacific region: Postâ€hoc analyses of pooled clinical study data. International Journal of Rheumatic Diseases, 2019, 22, 1094-1106.	1.9	12
259	Optimal Biologic Selection for Treatment of Psoriatic Arthritis: the Approach to Precision Medicine. Current Rheumatology Reports, 2019, 21, 21.	4.7	3
260	The JAK inhibitors: do they bring a paradigm shift for the management of rheumatic diseases?. Rheumatology, 2019, 58, i1-i3.	1.9	21
261	Usefulness of hemoglobin A1c and glycated albumin measurements for insulinoma screening: an observational case-control study. BMC Cancer, 2019, 19, 174.	2.6	4
262	Hypoglycemia Abrogates the Vascular Endothelial Protective Effect of Exenatide in Type 2 Diabetes Mellitus. Diabetes Therapy, 2019, 10, 1127-1132.	2.5	5
263	IL-6 and sIL-6R induces STAT3-dependent differentiation of human VSMCs into osteoblast-like cells through JMJD2B-mediated histone demethylation of RUNX2. Bone, 2019, 124, 53-61.	2.9	65
264	Expression of the genes encoding hypothalamic feeding-related neuropeptides in the streptozotocin-induced diabetic rats with variable hyperglycemia and hyperphagia. Neuropeptides, 2019, 75, 34-40.	2.2	2
265	Hypoglycemia in blood glucose level in type 2 diabetic Japanese patients by continuous glucose monitoring. Diabetology and Metabolic Syndrome, 2019, 11, 18.	2.7	1
266	Mediastinal and axillar lymphadenopathy in patients with rheumatoid arthritis: prevalence and clinical significance. Clinical Imaging, 2019, 55, 140-143.	1.5	5
267	AB0416â€A COMPARATIVE STUDY TO ASSESS THE EFFICACY, SAFETY, AND IMMUNOGENICITY OF YLB113 AND ETANERCEPT REFERENCE PRODUCT FOR THE TREATMENT OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS. , 2019, , .		0
268	SAT0126â€A PHASE 2 STUDY OF E6011, AN ANTI-FRACTALKINE MONOCLONAL ANTIBODY, IN PATIENTS WITH RHEUMATOID ARTHRITIS INADEQUATELY RESPONDING TO BIOLOGICS. , 2019, , .		0
269	THU0193â€EFFICACY OF TOFACITINIB MONOTHERAPY, TOFACITINIB WITH METHOTREXATE AND ADALIMUMAE WITH METHOTREXATE IN PATIENTS WITH EARLY (â‰ 2 YEARS) VS ESTABLISHED (>2 YEARS) RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF DATA FROM ORAL STRATEGY. , 2019, , .	3	3
270	THU0191â€UPADACITINIB AS MONOTHERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS AT 48 WE FROM THE SELECT-MONOTHERAPY STUDY. , 2019, , .	EKS	1

#	Article	IF	CITATIONS
271	Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3). Annals of the Rheumatic Diseases, 2019, 78, 1320-1332.	0.9	85
272	Small Cell Lung Cancer Patient with Anti-transcriptional Intermediary Factor 1Î ³ Antibody Who Developed Dermatomyositis after Successful Chemoradiotherapy. Internal Medicine, 2019, 58, 427-431.	0.7	3
273	Safety and effectiveness of abatacept in Japanese non-elderly and elderly patients with rheumatoid arthritis in an all-cases post-marketing surveillance. Modern Rheumatology, 2019, 29, 747-755.	1.8	17
274	Type I and II interferons commit to abnormal expression of chemokine receptor on B cells in patients with systemic lupus erythematosus. Clinical Immunology, 2019, 200, 1-9.	3.2	11
275	The front line of research into immunoglobin G4-related disease - Do autoantibodies cause immunoglobin G4-related disease?. Modern Rheumatology, 2019, 29, 214-218.	1.8	25
276	Scleroderma in an ice-cream shop worker. Rheumatology, 2019, 58, 1120-1121.	1.9	1
277	Significance of nailfold videocapillaroscopy in patients with idiopathic inflammatory myopathies. Rheumatology, 2019, 58, 120-130.	1.9	19
278	Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study. Rheumatology, 2019, 58, 997-1005.	1.9	16
279	Development of the Asia Pacific Lupus Collaboration cohort. International Journal of Rheumatic Diseases, 2019, 22, 425-433.	1.9	24
280	Response to: †Tocilizumab in patients with adult-onset Still's disease refractory to glucocorticoid treatment' by Lee. Annals of the Rheumatic Diseases, 2019, 78, e134-e134.	0.9	0
281	The two cases of acute acalculous cholecystitis associated with systemic lupus erythematosus (SLE) presented different clinical aspects. Modern Rheumatology Case Reports, 2019, 3, 114-118.	0.7	2
282	Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus. International Journal of Rheumatic Diseases, 2019, 22, 434-442.	1.9	17
283	Immunophenotype involved in IgG4-related disease. Modern Rheumatology, 2019, 29, 226-230.	1.8	17
284	Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study. Modern Rheumatology, 2019, 29, 767-774.	1.8	10
285	Clinical immunity in bone and joints. Journal of Bone and Mineral Metabolism, 2019, 37, 2-8.	2.7	45
286	Fatal Chronic Active Epstein-Barr Virus Infection in a Rheumatoid Arthritis Patient Treated with Abatacept. Internal Medicine, 2019, 58, 585-591.	0.7	6
287	Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data. Modern Rheumatology, 2019, 29, 756-766.	1.8	10
288	Efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: Subgroup analysis of a randomized, double-blind, multicenter, phase 3 study (SIRROUND-T). Modern Rheumatology, 2019, 29, 306-313.	1.8	3

#	Article	IF	CITATIONS
289	Evaluation of oxygen extraction fraction in systemic lupus erythematosus patients using quantitative susceptibility mapping. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 1648-1658.	4.3	8
290	Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis. Rheumatology, 2019, 58, 336-344.	1.9	92
291	3.State-of-the-art Internal Medicine in Joints and Bone. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 104a-111a.	0.0	0
292	Society of Internal Medicine, 2019, 108, 393-400.	0.0	0
293	3. State-of-the-art Internal Medicine in Joints and Bone. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 1700-1712.	0.0	0
294	Intracranial vessel wall lesions in patients with systematic lupus erythematosus. Journal of Magnetic Resonance Imaging, 2018, 48, 1237-1246.	3.4	12
295	Comparison of efficacy of TNF inhibitors and abatacept in patients with rheumatoid arthritis; Adjusted with propensity score matching. Clinical Immunology, 2018, 191, 67-74.	3.2	12
296	Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus. Modern Rheumatology, 2018, 28, 986-992.	1.8	50
297	Splicing variant of <i>WDFY4</i> augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. Annals of the Rheumatic Diseases, 2018, 77, 602-611.	0.9	51
298	Clinical practice guideline for Sjögren's syndrome 2017. Modern Rheumatology, 2018, 28, 383-408.	1.8	44
299	Efficacy and safety of sirukumab in Japanese patients with moderate to severe rheumatoid arthritis inadequately controlled by disease modifying anti-rheumatic drugs: Subgroup analysis of a phase 3 study. Modern Rheumatology, 2018, 28, 941-949.	1.8	3
300	Relationship between disease activity and patient-reported outcomes in rheumatoid arthritis: <i>Post hoc</i> analyses of overall and Japanese results from two phase 3 clinical trials. Modern Rheumatology, 2018, 28, 950-959.	1.8	14
301	Determinants of Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity in patients with rheumatoid arthritis: A <i>post hoc</i> analysis of overall and Japanese results from phase 3 clinical trials. Modern Rheumatology, 2018, 28, 960-967.	1.8	19
302	Podocyte and endothelial cell injury lead to nephrotic syndrome in proliferative lupus nephritis. Histopathology, 2018, 72, 1084-1092.	2.9	9
303	Correlation of T follicular helper cells and plasmablasts with the development of organ involvement in patients with IgG4-related disease. Rheumatology, 2018, 57, 514-524.	1.9	59
304	A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Annals of the Rheumatic Diseases, 2018, 77, 355-363.	0.9	196
305	Relation Between Hypoglycemia and Glycemic Variability in Type 2 Diabetes Patients with Insulin Therapy: A Study Based on Continuous Glucose Monitoring. Diabetes Technology and Therapeutics, 2018, 20, 140-146.	4.4	23
306	Comparison of the Effects of Teneligliptin and Sitagliptin, Two Dipeptidyl Peptidase 4 Inhibitors with Different Half-Lives, on Glucose Fluctuation and Glucagon-Like Peptide-1 in Type 2 Diabetes Mellitus. Journal of UOEH, 2018, 40, 1-9.	0.6	2

#	Article	IF	CITATIONS
307	Association Between Diabetic Microangiopathies and Glycemic Variability Assessed by Continuous Glucose Monitoring. Journal of UOEH, 2018, 40, 11-18.	0.6	7
308	Mechanisms and therapeutic targets for bone damage in rheumatoid arthritis, in particular the RANK-RANKL system. Current Opinion in Pharmacology, 2018, 40, 110-119.	3.5	63
309	Lymphocytic focus score is positively related to airway and interstitial lung diseases in primary Sjögren's syndrome. Respiratory Medicine, 2018, 137, 95-102.	2.9	44
310	JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial. Nephrology Dialysis Transplantation, 2018, 33, 1950-1959.	0.7	183
311	Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study. Modern Rheumatology, 2018, 28, 20-29.	1.8	33
312	Design characteristics of the Corrona Japan rheumatoid arthritis registry. Modern Rheumatology, 2018, 28, 95-100.	1.8	2
313	Twentyâ€fourâ€hour variations in blood glucose level in Japanese type 2 diabetes patients based on continuous glucose monitoring. Journal of Diabetes Investigation, 2018, 9, 75-82.	2.4	8
314	Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis. Rheumatology, 2018, 57, 164-174.	1.9	70
315	A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period. Modern Rheumatology, 2018, 28, 76-84.	1.8	17
316	Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis. Modern Rheumatology, 2018, 28, 58-65.	1.8	54
317	Relevance of P-glycoprotein on CXCR4 ⁺ B cells to organ manifestation in highly active rheumatoid arthritis. Modern Rheumatology, 2018, 28, 276-286.	1.8	14
318	Economic impact of adalimumab treatment in Japanese patients with rheumatoid arthritis from the adalimumab non-interventional trial for up-verified effects and utility (ANOUVEAU) study. Modern Rheumatology, 2018, 28, 39-47.	1.8	5
319	Comparison of effects of anagliptin and alogliptin on serum lipid profile in type 2 diabetes mellitus patients. Journal of Diabetes Investigation, 2018, 9, 360-365.	2.4	10
320	RANKL: A therapeutic target for bone destruction in rheumatoid arthritis. Modern Rheumatology, 2018, 28, 9-16.	1.8	63
321	Clinical efficacy, radiographic, and safety results of golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior therapy with disease-modifying antirheumatic drugs: Final results of the GO-MONO trial through week 120. Modern Rheumatology, 2018, 28, 770-779.	1.8	5
322	Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Annals of the Rheumatic Diseases, 2018, 77, 348-354.	0.9	279
323	Evaluation of the alternative classification criteria of systemic lupus erythematosus established by Systemic Lupus International Collaborating Clinics (SLICC). Modern Rheumatology, 2018, 28, 642-648.	1.8	16
324	Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials. Modern Rheumatology, 2018, 28, 583-591.	1.8	36

#	Article	IF	CITATIONS
325	B cell phenotypes, signaling and their roles in secretion of antibodies in systemic lupus erythematosus. Clinical Immunology, 2018, 186, 21-25.	3.2	32
326	Glycemic Profiling in Patients with Drug-NaÃ⁻ve Type 2 Diabetes by Continuous Glucose Monitoring. Journal of UOEH, 2018, 40, 287-297.	0.6	0
327	The role of nailfold videocapillaroscopy in patients with systemic sclerosis. Immunological Medicine, 2018, 41, 113-119.	2.6	9
328	Regulatory Mechanism of The Induction of Regulatory T Cells through Growth Factors Released by Human Mesenchymal Stem Cells. Critical Reviews in Immunology, 2018, 38, 471-478.	0.5	4
329	Abatacept in combination with methotrexate in Japanese biologic-naive patients with active rheumatoid arthritis: a randomised placebo-controlled phase IV study. RMD Open, 2018, 4, e000813.	3.8	11
330	Th22 Cells Promote Osteoclast Differentiation via Production of IL-22 in Rheumatoid Arthritis. Frontiers in Immunology, 2018, 9, 2901.	4.8	58
331	The Effects of Mitiglinide and Repaglinide on Postprandial Hyperglycemia in Patients Undergoing Methylprednisolone Pulse Therapy. Internal Medicine, 2018, 57, 65-70.	0.7	9
332	Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Annals of the Rheumatic Diseases, 2018, 77, 1720-1729.	0.9	129
333	Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis. Arthritis Research and Therapy, 2018, 20, 240.	3.5	39
334	Up-Regulation of TLR7-Mediated IFN-α Production by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus Erythematosus. Frontiers in Immunology, 2018, 9, 1957.	4.8	66
335	Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: A retrospective, observational study. International Journal of Rheumatic Diseases, 2018, 21, 1609-1618.	1.9	35
336	Risk Factors for Hypoglycemic Coma: A Study of 33 Patients on Insulin Therapy Who Were Transported to the Hospital by Ambulance. Internal Medicine, 2018, 57, 2923-2927.	0.7	0
337	IgG4-related Pleuritis with Elevated Adenosine Deaminase in Pleural Effusion. Internal Medicine, 2018, 57, 2251-2257.	0.7	23
338	Successful Management of Pregnancy in a Patient with Systemic Lupus Erythematosus-associated Pulmonary Arterial Hypertension. Internal Medicine, 2018, 57, 1655-1659.	0.7	4
339	Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study). Annals of the Rheumatic Diseases. 2018. 77. 1268-1275.	0.9	43
340	Characterization and Changes of Lymphocyte Subsets in Baricitinibâ€Treated Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2018, 70, 1923-1932.	5.6	26
341	Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System. Frontiers in Immunology, 2018, 9, 1510.	4.8	89
342	Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study. Scientific Reports, 2018, 8, 10262.	3.3	54

#	Article	IF	CITATIONS
343	Hydroxychloroquine efficiently suppresses inflammatory responses of human class-switched memory B cells via Toll-like receptor 9 inhibition. Clinical Immunology, 2018, 195, 1-7.	3.2	66
344	Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet, The, 2018, 392, 222-231.	13.7	396
345	Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naÃ ⁻ ve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study. Arthritis Research and Therapy, 2018, 20, 151.	3.5	12
346	Use of mesenchymal stem cells seeded on the scaffold in articular cartilage repair. Inflammation and Regeneration, 2018, 38, 4.	3.7	32
347	Effects of hypergravity on the gene expression of the hypothalamic feeding-related neuropeptides in mice via vestibular inputs. Peptides, 2018, 105, 14-20.	2.4	3
348	Hyperparathyroidism-jaw Tumor Syndrome Confirmed by Preoperative Genetic Testing. Internal Medicine, 2018, 57, 841-844.	0.7	10
349	Risk Factors of Hypoglycemia in Patients with Type 2 Diabetes Mellitus: A Study Based on Continuous Glucose Monitoring. Diabetes Technology and Therapeutics, 2018, 20, 603-612.	4.4	28
350	Expansion of T follicular helper-T helper 1 like cells through epigenetic regulation by signal transducer and activator of transcription factors. Annals of the Rheumatic Diseases, 2018, 77, 1354-1361.	0.9	62
351	Successful treatment with etanercept in a case of seronegative rheumatoid arthritis with corticosteroid/methotrexate-resistant pemphigus erythematosus. Modern Rheumatology Case Reports, 2018, 2, 137-142.	0.7	0
352	Increased remodelling of interstitial collagens and basement membrane is suppressed by treatment in patients with rheumatoid arthritis: serological evaluation of a one-year prospective study of 149 Japanese patients. Clinical and Experimental Rheumatology, 2018, 36, 462-470.	0.8	5
353	Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis: Large-Scale, Prospective, Single-Cohort ANOUVEAU Study. Advances in Therapy, 2017, 34, 686-702.	2.9	21
354	Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5â€years: integrated analysis of data from the global clinical trials. Annals of the Rheumatic Diseases, 2017, 76, 1253-1262.	0.9	316
355	Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial. Annals of the Rheumatic Diseases, 2017, 76, 1348-1356.	0.9	36
356	Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. Lancet, The, 2017, 389, 1206-1217.	13.7	94
357	Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. New England Journal of Medicine, 2017, 376, 652-662.	27.0	643
358	Discontinuation of tofacitinib after achieving low disease activity in patients with rheumatoid arthritis: a multicentre, observational study. Rheumatology, 2017, 56, 1293-1301.	1.9	19
359	Metabolic Reprogramming Commits Differentiation of Human CD27+IgD+ B Cells to Plasmablasts or CD27â^'IgDâ^' Cells. Journal of Immunology, 2017, 199, 425-434.	0.8	72
360	Peripheral Immunophenotyping Identifies Three Subgroups Based on T Cell Heterogeneity in Lupus Patients. Arthritis and Rheumatology, 2017, 69, 2029-2037.	5.6	74

#	Article	IF	CITATIONS
361	The occurrence of hypertrophic pachymeningitis with infiltration of IgG4-positive plasma cells and with different aetiology: report of three cases. Modern Rheumatology Case Reports, 2017, 1, 108-112.	0.7	1
362	Low disease activity for up to 3Âyears after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study. Arthritis Research and Therapy, 2017, 19, 56.	3.5	12
363	Determinants of hemoglobin A1c level in patients with type 2 diabetes after inâ€hospital diabetes education: A study based on continuous glucose monitoring. Journal of Diabetes Investigation, 2017, 8, 314-320.	2.4	8
364	Enlarged perivascular spaces are associated with the disease activity in systemic lupus erythematosus. Scientific Reports, 2017, 7, 12566.	3.3	22
365	Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy. Arthritis and Rheumatology, 2017, 69, 1960-1968.	5.6	182
366	Remission induction by Raising the dose of Remicade in RA (RRRR) study: Rationale and study protocol for a randomized controlled trial comparing for sustained clinical remission after discontinuation of infliximab in patients with rheumatoid arthritis. Contemporary Clinical Trials Communications, 2017, 8, 49-54.	1.1	4
367	Induction of Regulatory T Cells and Its Regulation with Insulin-like Growth Factor/Insulin-like Growth Factor Binding Protein-4 by Human Mesenchymal Stem Cells. Journal of Immunology, 2017, 199, 1616-1625.	0.8	53
368	Anti-PD-1 Antibody Therapy Induces Hashimoto's Disease with an Increase in Peripheral Blood Follicular Helper T Cells. Thyroid, 2017, 27, 1335-1336.	4.5	17
369	DMARD de-escalation — let the patient guide you. Nature Reviews Rheumatology, 2017, 13, 637-638.	8.0	14
370	Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. Annals of the Rheumatic Diseases, 2017, 76, 1853-1861.	0.9	83
371	A case of rheumatoid arthritis treated with infliximab who developed disseminated Penicillium marneffei infection after visit to Thailand. Modern Rheumatology Case Reports, 2017, 1, 43-48.	0.7	4
372	Genome-wide Association Study of Idiopathic Osteonecrosis of the Femoral Head. Scientific Reports, 2017, 7, 15035.	3.3	23
373	A multicenter phase II prospective clinical trial of glucocorticoid for patients with untreated IgG4-related disease. Modern Rheumatology, 2017, 27, 849-854.	1.8	62
374	Factors influencing interâ€day glycemic variability in diabetic outpatients receiving insulin therapy. Journal of Diabetes Investigation, 2017, 8, 69-74.	2.4	22
375	Efficacy and safety of tabalumab plus standard of care in Japanese patients with active systemic lupus erythematosus: Subgroup analyses of the ILLUMINATE-1 study. Modern Rheumatology, 2017, 27, 284-291.	1.8	7
376	Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab. Modern Rheumatology, 2017, 27, 237-245.	1.8	54
377	Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: The FIRST Bio study. Modern Rheumatology, 2017, 27, 217-226.	1.8	26
378	Role of P-glycoprotein on CD69+CD4+cells in the pathogenesis of proliferative lupus nephritis and non-responsiveness to immunosuppressive therapy. RMD Open, 2017, 3, e000423.	3.8	10

#	ARTICLE	IF	CITATIONS
379	The Effects of Pioglitazone on Bone Formation and Resorption Markers in Type 2 Diabetes Mellitus. Internal Medicine, 2017, 56, 1301-1306.	0.7	10
380	Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring. Diabetology and Metabolic Syndrome, 2017, 9, 60.	2.7	10
381	Comparative analysis of the effects of alogliptin and vildagliptin on glucose metabolism in type 2 diabetes mellitus. Endocrine Journal, 2017, 64, 179-189.	1.6	5
382	Introducing the launch of Modern Rheumatology Case Reports. Modern Rheumatology Case Reports, 2017, 1, 1-1.	0.7	0
383	Efficacy of Intravenous Cyclophosphamide Pulse Therapy for P-Glycoprotein-expressing B Cell-associated Active True Renal Lupus Vasculitis in Lupus Nephritis. Internal Medicine, 2017, 56, 1575-1580.	0.7	2
384	Clinical Features of Patients with Basedow's Disease and High Serum IgG4 Levels. Internal Medicine, 2017, 56, 1009-1013.	0.7	13
385	Abatacept therapy reduces CD28+CXCR5+ follicular helper-like T cells in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2017, 35, 562-570.	0.8	16
386	Current concepts in the management of rheumatoid arthritis. Korean Journal of Internal Medicine, 2016, 31, 210-218.	1.7	67
387	Overexpression of Peroxiredoxin 4 Affects Intestinal Function in a Dietary Mouse Model of Nonalcoholic Fatty Liver Disease. PLoS ONE, 2016, 11, e0152549.	2.5	28
388	Excess Visceral Adipose Tissue Worsens the Vascular Endothelial Function in Patients with Type 2 Diabetes Mellitus. Internal Medicine, 2016, 55, 3091-3095.	0.7	12
389	The changing landscape of biosimilars in rheumatology. Annals of the Rheumatic Diseases, 2016, 75, 974-982.	0.9	160
390	Response to: †Denosumab, cortical bone and bone erosion in rheumatoid arthritis' by Rossiniet al. Annals of the Rheumatic Diseases, 2016, 75, e71-e71.	0.9	2
391	Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). Annals of the Rheumatic Diseases, 2016, 75, 1917-1923.	0.9	81
392	Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1â€year outcomes of the HOPEFUL-2 study. RMD Open, 2016, 2, e000189.	3.8	21
393	Usefulness of nailfold videocapillaroscopy for systemic sclerosis. Inflammation and Regeneration, 2016, 36, 5.	3.7	7
394	Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose〓response study of AMG 162 (<i>D</i> enosumab) in patients with <i>R</i> heumato <i>I</i> d arthritis on methotrexate to <i>V</i> alidate inhibitory effect on bone <i>E</i> rosion (DRIVE)—a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. Annals of the Rheumatic Diseases, 2016, 75,	0.9	157
395	983-990. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Annals of the Rheumatic Diseases, 2016, 75, 1428-1437.	0.9	232
396	Chemical JAK inhibitors for the treatment of rheumatoid arthritis. Expert Opinion on Pharmacotherapy, 2016, 17, 2215-2225.	1.8	22

#	Article	IF	CITATIONS
397	Effectiveness of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial) Tj ETQq1	1 Q <i>8</i> 78431	44rgBT /Ove
398	Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies. International Journal of Rheumatic Diseases, 2016, 19, 1216-1225.	1.9	26
399	Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis. BioDrugs, 2016, 30, 407-419.	4.6	52
400	Stopping tumour necrosis factor-targeted biological DMARDs in rheumatoid arthritis. Rheumatology, 2016, 55, ii15-ii22.	1.9	21
401	Detrimental effects of high-fat diet loading on vascular endothelial function and therapeutic efficacy of ezetimibe and statins in patients with type 2 diabetes. Endocrine Journal, 2016, 63, 431-440.	1.6	14
402	BAFF- and APRIL-targeted therapy in systemic autoimmune diseases. Inflammation and Regeneration, 2016, 36, 6.	3.7	42
403	Baricitinib for the treatment of rheumatoid arthritis. Expert Review of Clinical Immunology, 2016, 12, 911-919.	3.0	29
404	Rationale and design of Diabetes Prevention with active Vitamin D (DPVD): a randomised, double-blind, placebo-controlled study. BMJ Open, 2016, 6, e011183.	1.9	20
405	Response to Dr Minota's Letter to the Editor of Modern Rheumatology Regarding a Study of Tofacitinib in Japanese Patients with Rheumatoid Arthritis. Modern Rheumatology, 2016, 26, 318-319.	1.8	0
406	Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Research and Therapy, 2016, 18, 34.	3.5	117
407	Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study). Rheumatology and Therapy, 2016, 3, 129-141.	2.3	3
408	B-cell subsets, signaling and their roles in secretion of autoantibodies. Lupus, 2016, 25, 850-856.	1.6	54
409	Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis. Expert Review of Clinical Immunology, 2016, 12, 1047-1057.	3.0	33
410	Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis. Modern Rheumatology, 2016, 26, 491-498.	1.8	80
411	Association of plasmacytoid dendritic cells with B cell infiltration in minor salivary glands in patients with Sjögren's syndrome. Modern Rheumatology, 2016, 26, 716-724.	1.8	21
412	Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study. Annals of the Rheumatic Diseases, 2016, 75, 1057-1064.	0.9	125
413	Safety, pharmacokinetics, and pharmacodynamics of epratuzumab in Japanese patients with moderate-to-severe systemic lupus erythematosus: Results from a phase 1/2 randomized study. Modern Rheumatology, 2016, 26, 87-93.	1.8	16
414	Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial. Modern Rheumatology, 2016, 26, 15-23.	1.8	53

#	Article	IF	CITATIONS
415	Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study. Journal of Rheumatology, 2016, 43, 504-511.	2.0	110
416	Evaluation of golimumab for the treatment of patients with active rheumatoid arthritis. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 319-326.	3.3	7
417	Efficacy of linagliptin and teneligliptin for glycemic control in type 2 diabetic patients with chronic kidney disease: assessment by continuous glucose monitoring; a pilot study. Diabetology International, 2016, 7, 368-374.	1.4	8
418	Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice. Modern Rheumatology, 2016, 26, 850-856.	1.8	14
419	<i>Post-hoc</i> analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis. Modern Rheumatology, 2016, 26, 473-480.	1.8	9
420	Clinically relevant radiographic progression in joint destruction in RA patients with abnormal MMP-3 or high levels of CRP despite 1-year treatment with infliximab. Modern Rheumatology, 2016, 26, 807-812.	1.8	8
421	Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity—results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Modern Rheumatology, 2016, 26, 651-661.	1.8	24
422	Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching. Annals of the Rheumatic Diseases, 2016, 75, 1321-1327.	0.9	42
423	The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Annals of the Rheumatic Diseases, 2016, 75, 75-83.	0.9	94
424	Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial. Modern Rheumatology, 2016, 26, 481-490.	1.8	13
425	Prevention of joint destruction in patients with high disease activity or high C-reactive protein levels: Post hoc analysis of the GO-FORTH study. Modern Rheumatology, 2016, 26, 323-330.	1.8	6
426	Analysis of bone metabolism during early stage and clinical benefits of early intervention with alendronate in patients with systemic rheumatic diseases treated with high-dose glucocorticoid: Early Dlagnosis and Treatment of OsteopoRosis in Japan (EDITOR-J) study. Journal of Bone and Mineral Metabolism, 2016, 34, 646-654.	2.7	15
427	Quantitative susceptibility mapping in patients with systemic lupus erythematosus: detection of abnormalities in normal-appearing basal ganglia. European Radiology, 2016, 26, 1056-1063.	4.5	16
428	Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy. Modern Rheumatology, 2016, 26, 80-86.	1.8	40
429	Spontaneous Differentiation of Human Mesenchymal Stem Cells on Poly-Lactic-Co-Glycolic Acid Nano-Fiber Scaffold. PLoS ONE, 2016, 11, e0153231.	2.5	46
430	Pancreas-protective effect of rituximab for acute-onset type 1 diabetes in the honeymoon period: a case report. Endocrinology, Diabetes and Metabolism Case Reports, 2016, 2016, 160020.	0.5	5
431	Psoriatic arthritis in Japan: difference in clinical features and approach to precision medicine. Clinical and Experimental Rheumatology, 2016, 34, 49-52.	0.8	14
432	Clinical, radiographic and functional efficacy of abatacept in routine care for rheumatoid arthritis patients: Abatacept Leading Trial for RA on Imaging Remission (ALTAIR) study. Clinical and Experimental Rheumatology, 2016, 34, 834-841.	0.8	4

#	Article	IF	CITATIONS
433	A multi-biomarker disease activity score for monitoring rheumatoid arthritis. Current Biomarker Findings, 2015, , 69.	0.4	2
434	Histamine inhibits differentiation of skin fibroblasts into myofibroblasts. Biochemical and Biophysical Research Communications, 2015, 463, 434-439.	2.1	16
435	Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: results from the Japanese studies. Modern Rheumatology, 2015, 25, 11-20.	1.8	11
436	Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry. Arthritis Research and Therapy, 2015, 17, 74.	3.5	53
437	Combination therapy for early rheumatoid arthritis: a treatment holiday perspective. Expert Review of Clinical Pharmacology, 2015, 8, 115-122.	3.1	4
438	Contribution of the Interleukinâ€6/STATâ€3 Signaling Pathway to Chondrogenic Differentiation of Human Mesenchymal Stem Cells. Arthritis and Rheumatology, 2015, 67, 1250-1260.	5.6	82
439	Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis. Modern Rheumatology, 2015, 25, 817-824.	1.8	69
440	A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: A retrospective observational study. Modern Rheumatology, 2015, 25, 344-349.	1.8	17
441	Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. Modern Rheumatology, 2015, 25, 514-521.	1.8	109
442	Activation of Syk in Peripheral Blood B Cells in Patients With Rheumatoid Arthritis: A Potential Target for Abatacept Therapy. Arthritis and Rheumatology, 2015, 67, 63-73.	5.6	59
443	Increased Syk phosphorylation leads to overexpression of TRAF6 in peripheral B cells of patients with systemic lupus erythematosus. Lupus, 2015, 24, 695-704.	1.6	38
444	Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside. Journal of Biochemistry, 2015, 158, 173-179.	1.7	63
445	Relevance of lymphocyte subsets to B cellâ€ŧargeted therapy in systemic lupus erythematosus. International Journal of Rheumatic Diseases, 2015, 18, 208-218.	1.9	19
446	Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus. Cardiovascular Diabetology, 2015, 14, 25.	6.8	38
447	Efficacy and safety of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis: Rheumatoid Arthritis with Orencia Trial toward Sjögren's syndrome Endocrinopathy (ROSE) trial—an open-label, one-year, prospective study—Interim analysis of 32 patients for 24 weeks. Modern Rheumatology, 2015, 25, 187-193.	1.8	34
448	Amplification of IL-21 signalling pathway through Bruton's tyrosine kinase in human B cell activation. Rheumatology, 2015, 54, 1488-1497.	1.9	41
449	Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study. Journal of Rheumatology, 2015, 42, 799-809.	2.0	39
450	Assessment of Risks of Pulmonary Infection During 12 Months Following Immunosuppressive Treatment for Active Connective Tissue Diseases: A Large-scale Prospective Cohort Study. Journal of Rheumatology, 2015, 42, 614-622.	2.0	8

#	Article	IF	CITATIONS
451	Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab. Arthritis Research and Therapy, 2015, 17, 280.	3.5	27
452	Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Annals of the Rheumatic Diseases, 2015, 74, 389-395.	0.9	149
453	Low complements and high titre of anti-Sm antibody as predictors of histopathologically proven silent lupus nephritis without abnormal urinalysis in patients with systemic lupus erythematosus. Rheumatology, 2015, 54, 405-412.	1.9	55
454	Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan. Rheumatology, 2015, 54, 683-691.	1.9	39
455	Disease control by regulation of P-glycoprotein on lymphocytes in patients with rheumatoid arthritis. World Journal of Experimental Medicine, 2015, 5, 225.	1.7	21
456	Human mesenchymal stem cells as a tool for joint repair in rheumatoid arthritis. Clinical and Experimental Rheumatology, 2015, 33, S58-62.	0.8	25
457	Local Delivery of Mesenchymal Stem Cells with Poly-Lactic-Co-Glycolic Acid Nano-Fiber Scaffold Suppress Arthritis in Rats. PLoS ONE, 2014, 9, e114621.	2.5	21
458	The possible mode of action of Tofacitinib, a JAK inhibitor. Inflammation and Regeneration, 2014, 34, 129-133.	3.7	1
459	<i>Clinical Trials Express:</i> Fracture Risk Reduction With Denosumab in Japanese Postmenopausal Women and Men With Osteoporosis: Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT). Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2599-2607.	3.6	138
460	Efficacy and safety of reducing duration of infliximab infusion. Modern Rheumatology, 2014, 24, 275-280.	1.8	4
461	Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: The HIKARI randomized, placebo-controlled trial. Modern Rheumatology, 2014, 24, 552-560.	1.8	40
462	Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis. Modern Rheumatology, 2014, 24, 405-409.	1.8	29
463	Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: a retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study. Modern Rheumatology, 2014, 24, 42-51.	1.8	11
464	Acquiring Chondrocyte Phenotype from Human Mesenchymal Stem Cells under Inflammatory Conditions. International Journal of Molecular Sciences, 2014, 15, 21270-21285.	4.1	22
465	Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors. Modern Rheumatology, 2014, 24, 399-404.	1.8	15
466	Effectiveness and Safety of Tocilizumab: Postmarketing Surveillance of 7901 Patients with Rheumatoid Arthritis in Japan. Journal of Rheumatology, 2014, 41, 15-23.	2.0	174
467	Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: Postmarketing surveillance report of 7740 patients. Modern Rheumatology, 2014, 24, 390-398.	1.8	100
468	Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro. Annals of the Rheumatic Diseases, 2014, 73, 2213-2215.	0.9	38

#	Article	IF	CITATIONS
469	Intensive Intervention Can Lead to a Treatment Holiday from Biological DMARDs in Patients with Rheumatoid Arthritis. Drugs, 2014, 74, 2129-2139.	10.9	15
470	IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab. Annals of the Rheumatic Diseases, 2014, 73, 1595-1597.	0.9	84
471	Low levels of 1,5-anhydro-D-glucitol are associated with vascular endothelial dysfunction in type 2 diabetes. Cardiovascular Diabetology, 2014, 13, 99.	6.8	18
472	Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study. Modern Rheumatology, 2014, 24, 734-743.	1.8	11
473	Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study. Modern Rheumatology, 2014, 24, 725-733.	1.8	12
474	Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial. Rheumatology, 2014, 53, 904-913.	1.9	27
475	Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial. Modern Rheumatology, 2014, 24, 715-724.	1.8	49
476	Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events. Rheumatology, 2014, 53, 914-918.	1.9	40
477	A case of teriparatide-induced severe hypophosphatemia and hypercalcemia. Journal of Bone and Mineral Metabolism, 2014, 32, 601-604.	2.7	12
478	IL-6-accelerated calcification by induction of ROR2 in human adipose tissue-derived mesenchymal stem cells is STAT3 dependent. Rheumatology, 2014, 53, 1282-1290.	1.9	52
479	Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus. Journal of Diabetes Investigation, 2014, 5, 313-319.	2.4	84
480	Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib. Expert Opinion on Pharmacotherapy, 2014, 15, 103-113.	1.8	17
481	Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study. Annals of the Rheumatic Diseases, 2014, 73, 536-543.	0.9	82
482	Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study. Arthritis Research and Therapy, 2014, 16, R43.	3.5	58
483	Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia [®] as Biological Intensive Treatment for RA (ORBIT) study. Modern Rheumatology, 2014, 24, 754-762.	1.8	15
484	Systemic Lupus Erythematosus. Academic Radiology, 2014, 21, 617-623.	2.5	2
485	The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Annals of the Rheumatic Diseases, 2014, 73, 2192-2198.	0.9	136
486	The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) database. Rheumatology International, 2014, 34, 1729-1736.	3.0	14

#	Article	IF	CITATIONS
487	The non-canonical Wnt5a/Ror2 signaling pathway in bone metabolism. Inflammation and Regeneration, 2014, 34, 103-108.	3.7	2
488	Clinical characteristics and risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case–control study of 17 patients. Modern Rheumatology, 2013, 23, 1085-93.	1.8	18
489	Effects of raloxifene on lipid and bone metabolism in postmenopausal women with type 2 diabetes. Journal of Bone and Mineral Metabolism, 2013, 31, 89-95.	2.7	15
490	A case of multiple brown tumors with primary hyperparathyroidism. Journal of Bone and Mineral Metabolism, 2013, 31, 123-127.	2.7	15
491	Dopamine D2-like receptor signaling suppresses human osteoclastogenesis. Bone, 2013, 56, 1-8.	2.9	45
492	Is It Possible to Withdraw Biologics From Therapy in Rheumatoid Arthritis?. Clinical Therapeutics, 2013, 35, 2028-2035.	2.5	22
493	Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study. Arthritis Research and Therapy, 2013, 15, R135.	3.5	39
494	Efficacy of combination of Ezetimibe 10Âmg and rosuvastatin 2.5Âmg versus rosuvastatin 5Âmg monotherapy for hypercholesterolemia in patients with type 2 diabetes. Lipids in Health and Disease, 2013, 12, 137.	3.0	39
495	Successful treatment of osteomalacia caused by renal tubular acidosis associated with Sjögren's syndrome. Modern Rheumatology, 2013, 23, 401-405.	1.8	4
496	Tofacitinib (CPâ€690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelveâ€month data from a twentyâ€four–month phase III randomized radiographic study. Arthritis and Rheumatism, 2013, 65, 559-570.	6.7	481
497	Efficacy of αâ€glucosidase inhibitors combined with dipeptidylâ€peptidaseâ€4 inhibitor (alogliptin) for glucose fluctuation in patients with typeÂ2 diabetes mellitus by continuous glucose monitoring. Journal of Diabetes Investigation, 2013, 4, 393-398.	2.4	13
498	A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study. Rheumatology, 2013, 52, 1202-1207.	1.9	79
499	Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus. Cardiovascular Diabetology, 2013, 12, 1.	6.8	215
500	Effects of pravastatin, atorvastatin, and rosuvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia. Diabetology International, 2013, 4, 117-125.	1.4	5
501	Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: a retrospective analysis of 6Âmonths of abatacept treatment in routine clinical practice. The ALTAIR study. Modern Rheumatology, 2013, , 1.	1.8	0
502	Next stage of RA treatment: is TNF inhibitor-free remission a possible treatment goal?. Annals of the Rheumatic Diseases, 2013, 72, ii124-ii127.	0.9	44
503	Janus kinase inhibitors in autoimmune diseases. Annals of the Rheumatic Diseases, 2013, 72, ii111-ii115.	0.9	350
504	Prevention of joint destruction by tacrolimus in patients with early rheumatoid arthritis: a post hoc analysis of a double-blind, randomized, placebo-controlled study. Modern Rheumatology, 2013, 23, 1045-1052.	1.8	7

#	Article	IF	CITATIONS
505	No increased mortality in patients with rheumatoid arthritis treated with biologics: results from the biologics register of six rheumatology institutes in Japan. Modern Rheumatology, 2013, 23, 945-952.	1.8	20
506	Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24â€weeks. Annals of the Rheumatic Diseases, 2013, 72, 1488-1495.	0.9	51
507	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Annals of the Rheumatic Diseases, 2013, 72, 482-492.	0.9	102
508	Clinical characteristics and risk factors for <i>Pneumocystis jirovecii</i> pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case–control study of 17 patients. Modern Rheumatology, 2013, 23, 1085-1093.	1.8	28
509	Safety and Effectiveness of 6 Months' Etanercept Monotherapy and Combination Therapy in Japanese Patients with Rheumatoid Arthritis: Effect of Concomitant Disease-modifying Antirheumatic Drugs. Journal of Rheumatology, 2013, 40, 1658-1668.	2.0	12
510	Validation of different sets of criteria for the diagnosis of Sjögren's syndrome in Japanese patients. Modern Rheumatology, 2013, 23, 219-225.	1.8	22
511	Activation of <scp>W</scp> nt5aâ€ <scp>R</scp> or2 signaling associated with epithelialâ€ŧoâ€mesenchymal transition of tubular epithelial cells during renal fibrosis. Genes To Cells, 2013, 18, 608-619.	1.2	35
512	JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical. Modern Rheumatology, 2013, 23, 415-424.	1.8	53
513	Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension. Endocrine Journal, 2013, 60, 563-570.	1.6	13
514	Dermal mast cell density in fingers reflects severity of skin sclerosis in systemic sclerosis. Modern Rheumatology, 2013, 23, 1151-1157.	1.8	16
515	IL-17 Inhibits Chondrogenic Differentiation of Human Mesenchymal Stem Cells. PLoS ONE, 2013, 8, e79463.	2.5	42
516	JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical. Modern Rheumatology, 2013, 23, 415-424.	1.8	27
517	Dermal mast cell density in fingers reflects severity of skin sclerosis in systemic sclerosis. Modern Rheumatology, 2013, 23, 1151-7.	1.8	8
518	4. Drugs Targeting Intracellular Molecule: JAK Inhibitor and Syk Inhibitor. Japanese Journal of Clinical Pharmacology and Therapeutics, 2013, 44, 23-27.	0.1	0
519	Regulatory role of mesenchymal stem cells in osteoclast differentiation. Inflammation and Regeneration, 2013, 33, 217-222.	3.7	1
520	Role of JAKs in myeloid cells and autoimmune diseases. Inflammation and Regeneration, 2013, 33, 131-135.	3.7	0
521	Successful treatment of osteomalacia caused by renal tubular acidosis associated with Sjögren's syndrome. Modern Rheumatology, 2013, 23, 401-405.	1.8	3
522	Prevention of joint destruction by tacrolimus in patients with early rheumatoid arthritis: a post hoc analysis of a double-blind, randomized, placebo-controlled study. Modern Rheumatology, 2013, 23, 1045-52.	1.8	2

#	Article	IF	CITATIONS
523	Discontinuation of biologics in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2013, 31, S22-7.	0.8	91
524	Phenotypic changes of lymphocyte in a patient with IgG4-related disease after corticosteroid therapy. Annals of the Rheumatic Diseases, 2012, 71, 2058-2059.	0.9	13
525	Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. Annals of the Rheumatic Diseases, 2012, 71, 817-824.	0.9	102
526	Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Modern Rheumatology, 2012, 22, 327-338.	1.8	38
527	Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules. Annals of the Rheumatic Diseases, 2012, 71, 1820-1826.	0.9	47
528	Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Modern Rheumatology, 2012, 22, 21-30.	1.8	1,294
529	B cell or T cell-dominant recurrence after rituximab therapy in patients with SLE. Annals of the Rheumatic Diseases, 2012, 71, 1749-1750.	0.9	11
530	Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis. Current Opinion in Rheumatology, 2012, 24, 319-326.	4.3	44
531	A novel clinical entity, IgC4-related disease (IgC4RD): general concept and details. Modern Rheumatology, 2012, 22, 1-14.	1.8	662
532	A case of catastrophic antiphospholipid antibody syndrome complicated with systemic lupus erythematosus, double positive for anti-cardiolipin/l²2 glycoprotein I and anti-phosphatidylserine/prothrombin autoantibodies. Modern Rheumatology, 2012, 22, 769-773.	1.8	4
533	Cell-autonomous role of TGFÎ ² and IL-2 receptors in CD4+ and CD8+ inducible regulatory T-cell generation during GVHD. Blood, 2012, 119, 5575-5583.	1.4	42
534	<i>Pneumocystis jirovecii</i> pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors. Modern Rheumatology, 2012, 22, 849-858.	1.8	46
535	Signal transduction inhibitors for the treatment of rheumatoid arthritis. Arthritis Research and Therapy, 2012, 14, .	3.5	0
536	Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Modern Rheumatology, 2012, 22, 498-508.	1.8	81
537	Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. Modern Rheumatology, 2012, 22, 382-393.	1.8	71
538	Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. Modern Rheumatology, 2012, 22, 814-822.	1.8	29
539	Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept. Modern Rheumatology, 2012, 22, 186-194.	1.8	6
540	A case of catastrophic antiphospholipid antibody syndrome complicated with systemic lupus erythematosus, double positive for anti-cardiolipin/l²2 glycoproteinÂl and anti-phosphatidylserine/prothrombin autoantibodies. Modern Rheumatology, 2012, 22, 769-773.	1.8	2

#	Article	IF	CITATIONS
541	Interleukinâ€1β induces differentiation of human mesenchymal stem cells into osteoblasts via the Wntâ€5a/receptor tyrosine kinase–like orphan receptor 2 pathway. Arthritis and Rheumatism, 2012, 64, 3355-3363.	6.7	132
542	Amplification of Toll-like receptor–mediated signaling through spleen tyrosine kinase in human B-cell activation. Journal of Allergy and Clinical Immunology, 2012, 129, 1594-1601.e2.	2.9	43
543	Telmisartan at 80 mg/Day Increases High-Molecular-Weight Adiponectin Levels and Improves Insulin Resistance in Diabetic Patients. Advances in Therapy, 2012, 29, 635-644.	2.9	27
544	Timeâ€dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis. Arthritis Care and Research, 2012, 64, 1125-1134.	3.4	47
545	The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferonâ€Î³ and interleukinâ€17 production by human CD4+ T cells. Arthritis and Rheumatism, 2012, 64, 1790-1798.	6.7	196
546	Treatment strategy based on targeting P-glycoprotein on peripheral lymphocytes in patients with systemic autoimmune disease. Clinical and Experimental Nephrology, 2012, 16, 102-108.	1.6	26
547	A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Modern Rheumatology, 2012, 22, 1-14.	1.8	453
548	Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Modern Rheumatology, 2012, 22, 327-338.	1.8	26
549	Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Modern Rheumatology, 2012, 22, 21-30.	1.8	947
550	Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity. Modern Rheumatology, 2012, 22, 814-822.	1.8	21
551	Mesenchymal stem cells: A new treatment tool for rheumatoid arthritis. Inflammation and Regeneration, 2012, 32, 188-192.	3.7	1
552	Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept. Modern Rheumatology, 2012, 22, 186-194.	1.8	2
553	Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Modern Rheumatology, 2011, 21, 122-133.	1.8	65
554	Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Modern Rheumatology, 2011, 21, 343-351.	1.8	95
555	Efficacité de l'étanercept dans une cirrhose biliaire primitive associée à une polyarthrite rhumatoÃ⁻de. Revue Du Rhumatisme (Edition Francaise), 2011, 78, 589-590.	0.0	0
556	Incidence and Risk Factors for Serious Infection in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. Journal of Rheumatology, 2011, 38, 1258-1264.	2.0	141
557	Recent progress in small molecular products for the treatment of joint and bone diseases: an over view. Inflammation and Regeneration, 2011, 31, 341-343.	3.7	0
558	JAK inhibitor: tofacitinib, a new disease modifying anti-rheumatic drug. Inflammation and Regeneration, 2011, 31, 349-353.	3.7	1

#	Article	IF	CITATIONS
559	Pericarditis induced by prophylactic administration of isoniazid in a patient with rheumatoid arthritis. Joint Bone Spine, 2011, 78, 99-100.	1.6	2
560	Successful treatment of primary biliary cirrhosis with etanercept in a patient with rheumatoid arthritis. Joint Bone Spine, 2011, 78, 535-536.	1.6	9
561	Phase II study of tofacitinib (CPâ€690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care and Research, 2011, 63, 1150-1158.	3.4	259
562	Human mesenchymal stem cells inhibit osteoclastogenesis through osteoprotegerin production. Arthritis and Rheumatism, 2011, 63, 1658-1667.	6.7	73
563	Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Annals of the Rheumatic Diseases, 2011, 70, 2148-2151.	0.9	166
564	Phenotypic Changes of Lymphocytes in Patients with Systemic Lupus Erythematosus Who Are in Longterm Remission After B Cell Depletion Therapy with Rituximab. Journal of Rheumatology, 2011, 38, 633-641.	2.0	60
565	Continuation of Methotrexate Resulted in Better Clinical and Radiographic Outcomes Than Discontinuation upon Starting Etanercept in Patients with Rheumatoid Arthritis: 52-week Results from the JESMR Study. Journal of Rheumatology, 2011, 38, 1585-1592.	2.0	75
566	Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease. Modern Rheumatology, 2011, 21, 184-191.	1.8	69
567	Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs—a multicenter, double-blind, parallel-group trial. Modern Rheumatology, 2011, 21, 458-468.	1.8	21
568	Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patientsREACTION 52-week study. Rheumatology, 2011, 50, 1908-1915.	1.9	78
569	The REAL database reveals no significant risk of serious infection during treatment with a methotrexate dose of more than 8 mg/week in patients with rheumatoid arthritis. Modern Rheumatology, 2011, 21, 444-448.	1.8	16
570	Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease. Modern Rheumatology, 2011, 21, 184-191.	1.8	50
571	Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Modern Rheumatology, 2011, 21, 343-351.	1.8	51
572	Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs—a multicenter, double-blind, parallel-group trial. Modern Rheumatology, 2011, 21, 458-468.	1.8	12
573	Jak and Syk: Emerging their relevance to the treatment of inflammatory diseases. Inflammation and Regeneration, 2011, 31, 237-244.	3.7	6
574	Denosumab for the treatment of joint and bone diseases. Inflammation and Regeneration, 2011, 31, 344-348.	3.7	1
575	C5a promotes migration, proliferation, and vessel formation in endothelial cells. Inflammation Research, 2010, 59, 659-666.	4.0	38
576	Advanced glycation end products increase endothelial permeability through the RAGE/Rho signaling pathway. FEBS Letters, 2010, 584, 61-66.	2.8	100

#	Article	IF	CITATIONS
577	Mast cell–derived tryptase inhibits apoptosis of human rheumatoid synovial fibroblasts via rhoâ€mediated signaling. Arthritis and Rheumatism, 2010, 62, 952-959.	6.7	46
578	Etanercept overcomes P-glycoprotein-induced drug resistance in lymphocytes of patients with intractable rheumatoid arthritis. Modern Rheumatology, 2010, 20, 139-146.	1.8	20
579	Tacrolimus, a Calcineurin Inhibitor, Overcomes Treatment Unresponsiveness Mediated by P-glycoprotein on Lymphocytes in Refractory Rheumatoid Arthritis. Journal of Rheumatology, 2010, 37, 512-520.	2.0	56
580	Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Annals of the Rheumatic Diseases, 2010, 69, 1286-1291.	0.9	251
581	Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. Modern Rheumatology, 2010, 20, 531-538.	1.8	60
582	Galectin-9 induces osteoblast differentiation through the CD44/Smad signaling pathway. Biochemical and Biophysical Research Communications, 2010, 394, 317-322.	2.1	47
583	Etanercept overcomes P-glycoprotein-induced drug resistance in lymphocytes of patients with intractable rheumatoid arthritis. Modern Rheumatology, 2010, 20, 139-146.	1.8	10
584	Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. Modern Rheumatology, 2010, 20, 531-538.	1.8	43
585	Effects of anti-TNF-Â antibody infliximab in refractory entero-Behcet's disease. Rheumatology, 2009, 48, 1012-1013.	1.9	51
586	Postmarketing Surveillance of the Safety and Effectiveness of Etanercept in Japan. Journal of Rheumatology, 2009, 36, 898-906.	2.0	167
587	Usefulness of initial histological features for stratifying Sjogren's syndrome responders to mizoribine therapy. Rheumatology, 2009, 48, 1279-1282.	1.9	20
588	Interaction of Galectin-9 With Lipid Rafts Induces Osteoblast Proliferation Through the c-Src/ERK Signaling Pathway. Journal of Bone and Mineral Research, 2008, 23, 278-286.	2.8	33
589	Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: Preventive and therapeutic effects on experimental autoimmune encephalomyelitis. Biochemical and Biophysical Research Communications, 2008, 373, 286-291.	2.1	131
590	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). Modern Rheumatology, 2008, 18, 146-152.	1.8	61
591	Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Modern Rheumatology, 2008, 18, 460-464.	1.8	42
592	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J). Modern Rheumatology, 2008, 18, 447-454.	1.8	40
593	Alendronate Protects Premenopausal Women from Bone Loss and Fracture Associated with High-dose Glucocorticoid Therapy. Journal of Rheumatology, 2008, 35, 2249-2254.	2.0	50

Reply to Dr Pollono. Endocrine Journal, 2008, 55, 949.

1.6 0

#	Article	IF	CITATIONS
595	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). Modern Rheumatology, 2008, 18, 146-152.	1.8	43
596	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J). Modern Rheumatology, 2008, 18, 447-454.	1.8	29
597	Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Modern Rheumatology, 2008, 18, 460-464.	1.8	32
598	Enhanced effect of high-dose leukocytapheresis using a large filter in rheumatoid arthritis. Modern Rheumatology, 2007, 17, 481-485.	1.8	15
599	A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Modern Rheumatology, 2007, 17, 191-197.	1.8	107
600	Leflunomide Inhibits PDK1/Akt Pathway and Induces Apoptosis of Human Mast Cells. Journal of Immunology, 2007, 179, 6479-6484.	0.8	40
601	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Modern Rheumatology, 2007, 17, 28-32.	1.8	56
602	Treatment of Inflammatory Immunologic Disease 4. B Cell Targeting Therapy Using the Anti-CD20 Antibody Rituximab in Inflammatory Autoimmune Diseases. Internal Medicine, 2007, 46, 1313-1315.	0.7	18
603	Efficacy and safety of mizoribine for the treatment of Sjögren's syndrome: a multicenter open-label clinical trial. Modern Rheumatology, 2007, 17, 464-469.	1.8	33
604	Small GTPase Rho signaling is involved in β1 integrin-mediated up-regulation of intercellular adhesion molecule 1 and receptor activator of nuclear factor κB ligand on osteoblasts and osteoclast maturation. Biochemical and Biophysical Research Communications, 2007, 356, 279-285.	2.1	13
605	A case of life-threatening refractory polychondritis successfully treated with combined intensive immunosuppressive therapy with methotrexate. Modern Rheumatology, 2007, 17, 144-147.	1.8	10
606	Activation signal transduction by \hat{l}^21 integrin in T cells from patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2007, 56, 1559-1568.	6.7	25
607	Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Modern Rheumatology, 2007, 17, 28-32.	1.8	46
608	A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Modern Rheumatology, 2007, 17, 191-197.	1.8	92
609	Efficacy and safety of mizoribine for the treatment of Sjögren's syndrome: a multicenter open-label clinical trial. Modern Rheumatology, 2007, 17, 464-469.	1.8	24
610	Enhanced effect of high-dose leukocytapheresis using a large filter in rheumatoid arthritis. Modern Rheumatology, 2007, 17, 481-485.	1.8	10
611	Acetylation of an Ets Transcription Factor PU.1 Suppresses Its Transcriptional Activity Blood, 2007, 110, 2402-2402.	1.4	0
612	Glycated albumin and cross-linking of CD44 induce scavenger receptor expression and uptake of oxidized LDL in human monocytes. Biochemical and Biophysical Research Communications, 2006, 339, 846-851.	2.1	13

#	Article	IF	CITATIONS
613	Increased expression levels of monocyte CCR2 and monocyte chemoattractant protein-1 in patients with diabetes mellitus. Biochemical and Biophysical Research Communications, 2006, 344, 780-785.	2.1	64
614	Anti-CD20 and other novel biotherapies for systemic lupus erythematosus. APLAR Journal of Rheumatology, 2006, 9, 413-418.	0.2	3
615	Growth suppression of human mast cells expressing constitutively active c-kit receptors by JNK inhibitor SP600125. Genes To Cells, 2006, 11, 983-992.	1.2	11
616	Attempt to correct abnormal signal transduction in T lymphocytes from systemic lupus erythematosus patients. Autoimmunity Reviews, 2006, 5, 143-144.	5.8	15
617	Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Annals of the Rheumatic Diseases, 2006, 66, 470-475.	0.9	282
618	Fragmented Hyaluronan Induces Transcriptional Up-regulation of the Multidrug Resistance-1 Gene in CD4+ T Cells. Journal of Biological Chemistry, 2006, 281, 38089-38097.	3.4	19
619	Human urinary trypsin inhibitor bolus infusion improved severe interstitial pneumonia in mixed connective tissue disease. Modern Rheumatology, 2005, 15, 374-380.	1.8	5
620	Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2005, 52, 1676-1683.	6.7	80
621	Overcoming treatment unresponsiveness mediated by P-glycoprotein overexpression on lymphocytes in refractory active systemic lupus erythematosus. Modern Rheumatology, 2005, 15, 28-32.	1.8	15
622	Osteoblasts and Osteoclasts in Bone Remodeling and Inflammation. Inflammation and Allergy: Drug Targets, 2005, 4, 325-328.	3.1	321
623	Glucocorticoid-induced osteoporosis: skeletal manifestations of glucocorticoid use and 2004 Japanese Society for Bone and Mineral Research-proposed guidelines for its management. Modern Rheumatology, 2005, 15, 163-168.	1.8	9
624	Small GTP-binding protein Rho-mediated signaling promotes proliferation of rheumatoid synovial fibroblasts. Arthritis Research, 2005, 7, R476.	2.0	16
625	Overcoming treatment unresponsiveness mediated by P-glycoprotein overexpression on lymphocytes in refractory active systemic lupus erythematosus. Modern Rheumatology, 2005, 15, 28-32.	1.8	14
626	Glucocorticoid-induced osteoporosis: skeletal manifestations of glucocorticoid use and 2004 Japanese Society for Bone and Mineral Research-proposed guidelines for its management. Modern Rheumatology, 2005, 15, 163-168.	1.8	5
627	Effects of oxygen therapy during sleep in chronic dialysis patients with sleep-disordered breathing. Nihon Toseki Igakkai Zasshi, 2005, 38, 1187-1194.	0.1	0
628	Human urinary trypsin inhibitor bolus infusion improved severe interstitial pneumonia in mixed connective tissue disease. Modern Rheumatology, 2005, 15, 374-380.	1.8	6
629	Transcriptional regulation of multidrug resistance-1 gene by interleukin-2 in lymphocytes. Genes To Cells, 2004, 9, 1265-1273.	1.2	57
630	Macrophage Inflammatory Protein-1α Induces Hypercalcemia in Adult T-Cell Leukemia. Journal of Bone and Mineral Research, 2004, 19, 1105-1111.	2.8	42

#	Article	IF	CITATIONS
631	Acro-Osteolysis and Symphalangism Mutations. Journal of Bone and Mineral Research, 2004, 20, 160-160.	2.8	0
632	Genome-wide linkage analysis of type 2 diabetes mellitus reconfirms the susceptibility locus on 11p13–p12 in Japanese. Journal of Human Genetics, 2004, 49, 629-634.	2.3	18
633	Severe hypercalcemia and hypernatremia associated with calcipotriol for treatment of psoriasis. Journal of Bone and Mineral Metabolism, 2004, 22, 159-162.	2.7	16
634	Induction of RANKL expression and osteoclast maturation by the binding of fibroblast growth factor 2 to heparan sulfate proteoglycan on rheumatoid synovial fibroblasts. Arthritis and Rheumatism, 2004, 50, 2450-2458.	6.7	61
635	Expression of the Chk2 Gene Is Downregulated in Hodgkin's Lymphoma Cell Lines Via Epigenetic Mechanisms Blood, 2004, 104, 429-429.	1.4	Ο
636	Etidronate prevents high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseases. Journal of Rheumatology, 2004, 31, 163-6.	2.0	28
637	Adult-Onset Idiopathic Progressive Acro-Osteolysis With Proximal Symphalangism. Journal of Bone and Mineral Research, 2003, 19, 165-167.	2.8	7
638	Inter- and intracellular signaling in secondary osteoporosis. Journal of Bone and Mineral Metabolism, 2003, 21, 61-66.	2.7	13
639	?1 integrin-mediated signaling induces intercellular adhesion molecule 1 and Fas on rheumatoid synovial cells and Fas-mediated apoptosis. Arthritis and Rheumatism, 2003, 48, 1239-1248.	6.7	32
640	Crosslinking of CD44 on human osteoblastic cells upregulates ICAM-1 and VCAM-1. FEBS Letters, 2003, 539, 45-50.	2.8	36
641	Monocyte chemoattractant protein-1 induces scavenger receptor expression and monocyte differentiation into foam cells. Biochemical and Biophysical Research Communications, 2003, 305, 380-385.	2.1	49
642	Efficacy of mizoribine treatment in patients with Sjögren's syndrome: an open pilot trial. Modern Rheumatology, 2003, 13, 339-345.	1.8	12
643	Severe skin ulceration associated with Wegener's granulomatosis: successful treatment with hyperbaric oxygen and prostaglandin E ₁ . Modern Rheumatology, 2003, 13, 346-349.	1.8	0
644	β1 Integrin/Focal Adhesion Kinase-mediated Signaling Induces Intercellular Adhesion Molecule 1 and Receptor Activator of Nuclear Factor IºB Ligand on Osteoblasts and Osteoclast Maturation. Journal of Biological Chemistry, 2003, 278, 45368-45374.	3.4	68
645	Efficacy of mizoribine treatment in patients with Sj�gren?s syndrome: an open pilot trial. Modern Rheumatology, 2003, 13, 339-345.	1.8	2
646	Severe skin ulceration associated with Wegener?s granulomatosis: successful treatment with hyperbaric oxygen and prostaglandin E1. Modern Rheumatology, 2003, 13, 346-349.	1.8	0
647	Autocrine Induction of the Human Pro-IL-1Î ² Gene Promoter by IL-1Î ² in Monocytes. Journal of Immunology, 2002, 168, 1984-1991.	0.8	60
648	H-Ras/Mitogen-activated Protein Kinase Pathway Inhibits Integrin-mediated Adhesion and Induces Apoptosis in Osteoblasts. Journal of Biological Chemistry, 2002, 277, 21446-21452.	3.4	39

#	Article	IF	CITATIONS
649	Hypoxia-inducible factor-1α induces cell cycle arrest of endothelial cells. Genes To Cells, 2002, 7, 143-149.	1.2	63
650	Clinical implication of cyclosporin for systemic autoimmune diseases: relevance to multidrug resistance. Japanese Journal of Clinical Immunology, 2002, 25, 110-114.	0.0	1
651	Pneumocystis carinii pneumonia in patients with connective tissue diseases. Japanese Journal of Clinical Immunology, 2002, 25, 310-318.	0.0	3
652	Activated Platelets and Endothelial Cell Interaction with Neutrophils under Flow Conditions Internal Medicine, 2001, 40, 1085-1092.	0.7	41
653	Fractalkine, a CX 3 Câ€chemokine, functions predominantly as an adhesion molecule in monocytic cell line THPâ€1. Immunology and Cell Biology, 2001, 79, 298-302.	2.3	86
654	Down-regulation of α6 integrin, an anti-oncogene product, by functional cooperation of H-Ras and c-Myc. Genes To Cells, 2001, 6, 337-343.	1.2	12
655	CD44 Is the Physiological Trigger of Fas Up-Regulation on Rheumatoid Synovial Cells. Journal of Immunology, 2001, 167, 1198-1203.	0.8	67
656	CD44 stimulation down-regulates Fas expression and Fas-mediated apoptosis of lung cancer cells. International Immunology, 2001, 13, 1309-1319.	4.0	58
657	The role of chemokines and adhesion molecules in the pathogenesis of rheumatoid arthritis. Drugs of Today, 2001, 37, 477.	2.4	21
658	Intercellular adhesion molecule 1 underlies the functional heterogeneity of synovial cells in patients with rheumatoid arthritis: Involvement of cell cycle machinery. Arthritis and Rheumatism, 2000, 43, 2513-2522.	6.7	10
659	Intercellular Adhesion Molecule 1 Discriminates Functionally Different Populations of Human Osteoblasts: Characteristic Involvement of Cell Cycle Regulators. Journal of Bone and Mineral Research, 2000, 15, 1912-1923.	2.8	80
660	Constitutive activation of LIL-Stat in adult T-cell leukemia cells. Blood, 2000, 95, 2715-2718.	1.4	8
661	Intercellular adhesion molecule-1 (ICAM-1) mediated gene delivery to rheumatoid synovial cells using the Fab fragments of anti-ICAM-1 monoclonal antibody. Japanese Journal of Clinical Immunology, 2000, 23, 533-537.	0.0	1
662	Additive combination of actarit and methotrexate in the treatment of refractory rheumatoid arthritis. Modern Rheumatology, 2000, 10, 103-109.	1.8	1
663	Activation of Leukocyte Function-Associated Antigen-1 on Adult T-cell Leukemia Cells. Leukemia and Lymphoma, 1999, 36, 15-23.	1.3	13
664	H-Ras signals to cytoskeletal machinery in induction of integrin-mediated adhesion of T cells. Journal of Immunology, 1999, 163, 6209-16.	0.8	57
665	Heparan sulfate proteoglycan on endothelium efficiently induces integrin-mediated T cell adhesion by immobilizing chemokines in patients with rheumatoid synovitis. Arthritis and Rheumatism, 1998, 41, 1365-1377.	6.7	51
666	Induction of expression of MHC-class-II antigen on human thyroid carcinoma by wild-type p53. , 1998, 75, 391-395.		15

#	Article	IF	CITATIONS
667	A Critical Role for Cyclin C in Promotion of the Hematopoietic Cell Cycle by Cooperation with c-Myc. Molecular and Cellular Biology, 1998, 18, 3445-3454.	2.3	41
668	Constitutive Chemokine Production Results in Activation of Leukocyte Function-Associated Antigen-1 on Adult T-Cell Leukemia Cells. Blood, 1998, 91, 3909-3919.	1.4	75
669	Chemokine and Cellular Adhesion in the Context of Heparan Sulfate Proteoglycan Trends in Glycoscience and Glycotechnology, 1998, 10, 153-160.	0.1	5
670	Constitutive up-regulation of integrin-mediated adhesion of tumor-infiltrating lymphocytes to osteoblasts and bone marrow-derived stromal cells. Cancer Research, 1998, 58, 4138-45.	0.9	27
671	Chondrocytes Are Regulated by Cellular Adhesion Through CD44 and Hyaluronic Acid Pathway. Journal of Bone and Mineral Research, 1997, 12, 1657-1663.	2.8	132
672	Distinct phenotype of leukemic T cells with various tissue tropisms. Journal of Immunology, 1997, 158, 3822-9.	0.8	39
673	Osteoblasts are regulated by the cellular adhesion through ICAM-1 and VCAM-1. Journal of Bone and Mineral Research, 1995, 10, 1462-1469.	2.8	97
674	CD45RB expression defines two interconvertible subsets of human CD4+ T cells with memory function. European Journal of Immunology, 1994, 24, 1240-1243.	2.9	21
675	Differential Expression of Integrins α6 and α4 Determines Pathways in Human Peripheral CD4+ T Cell Differentiation. Cell Adhesion and Communication, 1994, 2, 403-415.	1.7	8
676	Proteoglycans on endothelial cells present adhesion-inducing cytokines to leukocytes. Trends in Immunology, 1993, 14, 111-115.	7.5	412
677	T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-lβ. Nature, 1993, 361, 79-82.	27.8	869
678	Suppressive effect of interleukin-4 on the differentiation of M1 and HL60 myeloid leukemic cells. Journal of Leukocyte Biology, 1993, 54, 133-137.	3.3	5
679	Interleukinâ€4 induces proliferation of adult Tâ€cell leukemia cells. European Journal of Haematology, 1993, 50, 133-140.	2.2	14
680	Lymphocyte interactions with endothelial cells. Trends in Immunology, 1992, 13, 106-112.	7.5	669
681	Bâ€B Cell Interactions in the Spontaneous Activation of B Cells in Autoimmune NZB Mice. Microbiology and Immunology, 1991, 35, 741-753.	1.4	4
682	Suppressive Activity of Interleukin 4 on the Induction of Antigen-specific Cytotoxic T Cells in Humans. Japanese Journal of Cancer Research, 1991, 82, 585-592.	1.7	10
683	Inhibitory Effect of IL-1 on the TSH Dependent Growth of Rat Thyroid Cells (FRTL-5) Endocrinologia Japonica, 1990, 37, 619-627.	0.5	5
684	Antiviral and Antiproliferative Activities of Recombinant Human Interferon α2, β and γ on HTLV-â and ATL Cells <i>in Vitro</i> . Journal of UOEH, 1990, 12, 149-161.	0.6	6

#	Article	IF	CITATIONS
685	Corrigendum to: Digital pitting scars are associated with a severe disease course and death in systemic sclerosis: a study from the EUSTAR cohort. Rheumatology, 0, , .	1.9	0